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INTRODUCTION 
Avian infectious bronchitis virus (IBV) has been deter­
mined to be the etiologic agent of an acute, highly conta­
gious, panzootic, respiratory disease occurring in chickens 
of all ages. IBV has been implicated in ovarian lesions 
with a resultant reduction in egg production and a nephritis-
nephrosis syndrome. 
Methods of controlling this disease by immunization 
have produced inconclusive results. The use of live IBV 
has been confined to egg passage material, that will pro­
duce immunity for periods up to 18 months. This method 
of immunization amounts to controlled exposure and gener­
ally cannot be used to immunize chickens close to laying 
age, due to losses in egg production. 
In England and some western European countries the use 
of live IBV vaccines is prohibited. The majority of IBV 
strains isolated in these countries belong to the Massachu­
setts serotype. These strains have been used in production 
of inactivated IBV vaccines. Immunizations with inactivated 
vaccines have failed to induce neutralizing antibody against 
standard Massachusetts type strains. One vaccine has been 
reported to produce antibodies to its homologous strain used 
in preparation of the vaccine. 
Two aspects of the immune response of chickens to IBV 
were selected for this study: 1. The adaptation and 
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propagation of IBV-33 in chicken embryo kidney cells and its 
ability to induce immunity in susceptible chickens, to sub­
sequent challenge. Also determination of the effect of suc­
cessive passage in cell cultures on virulence for chicken 
embryos. 2. Inactivation of IBV-33 by Beta-propiolactone 
and its use as an immunizing agent. 
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REVIEW OF LITERATURE 
Etiology of Avian Infectious 
Bronchitis Virus 
Schalk and Hawn (1) in 1931 authored the first descrip­
tion of a highly infectious respiratory disease that caused 
heavy mortality in chicks and called it infectious bronchitis 
of baby chicks. The virus etiology of this disease was sug­
gested by Bushnell and Brandly (2), but was first estab­
lished conclusively by Beach and Schalm (3), and Beaudette 
and Hudson (4) by passing supernatant fluid of ground infec­
ted tissue through all grades of Berkefeld filters. 
Infectious bronchitis virus (IBV) was tentatively class­
ified by Berry et al. (5) and Berry and Cruickshank (6) as a 
Myxovirus on basis of ether sensitivity, size of 80 to 120 
millimicrons, pear shaped surface projections, no hemaggluti­
nin or neuraminidase and a medium sized ribonucleoprotein 
core. Corbo and Cunningham (7) have demonstrated presence 
of a hemagglutinin in trypsin-modified IBV. 
Almeida et al. (8) proposed the name of CORONAVIRUSES 
for IBV and a group of IBV-like viruses of human and murine 
origin. This suggestion has been accepted by members of the 
Myxovirus Study Group under the International Committee for 
Nomenclature of viruses. 
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Isolation and Pathology of 
IBV in Chicken Embryos 
Beaudette and Hudson (4) were the first to cultivate IBV 
in chicken embryos. They observed that the first 6 passages 
were relatively non-lethal to embryos. An increase in viru­
lence on further passage was noted, with death resulting in 
a majority of embryos. Gross lesions were dwarfing of the 
embryo, thinning of the chorioallantoic membrane and thick­
ening of yolk material. Delaplane and Stuart (9] confirmed 
these findings and in addition found white, opaque, circular 
lesions on chorioallantoic membranes at point of inoculation. 
With successive passage in eggs, virus increased in lethal­
ity for embryos, with a progressive decrease in time required 
to produce death of embryos. An increase in lethality for 
embryos was accompanied by a decrease in virulence for 
chicks. 
Later, Delaplane (10] reported that an allantoic cavity 
route of inoculation was superior to chorioallantoic membrane 
route, for initial isolation of virus, as evidenced by 
dwarfing in first passage. 
Fabricant (11) confirmed findings of previous authors 
as to gross pathologic changes of chicken embryos inoculated 
with IBV. In addition he described "curling" of embryos into 
a ball-like shape. This curling precedes dwarfing, and 
occurs in infected embryos of normal size. Loomis et al. 
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(12) reported immature feather development and presence of 
yellowish foci of urates in the mesonephros. This latter 
observation was confirmed by Hitchner and White (13) and 
Hofstad (14). These workers consider presence of urates of 
diagnostic importance in absence of other gross lesions. 
Cunningham and El Dardiry (15) reported on distribution 
of IBV in chicken embryos inoculated via the allantoic sac. 
Highest concentrations of virus was found in chorioallan­
toic membrane, followed in order by allantoic fluid, amni­
otic fluid, and liver. The yolk was innocuous. Maximum titer 
of virus was obtained at 36 hours after inoculation. Virus 
titer was greater in materials collected from living embryos 
than from embryos dead at the same post inoculation interval. 
Fabricant (16) corroborated these findings and stated that 
24 hours after inoculation, titer of virus in allantoic 
fluid was at a maximum and that it decreases progressively 
after 36 and 48 hours. 
Serologic Relationships Among 
Strains of IBV 
Serologic differences among IBV isolates were first re­
ported by Hofstad (17), following aerosol exposure of strain 
33 and subsequent challenge with isolate number 581. 
Jungherr et al. (18) confirmed these results and were first to 
suggest a classification as to serotypes: Massachusetts type 
and Connecticut type. The Massachusetts type included two 
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strains No. 66570 isolated by Beaudette and Hudson (4] and 
No. 82828 (IBV-41) isolated by Dr. Henry Van Roekel, Univer­
sity of Massachusetts, in May 1941. Connecticut type No. 
A5968 (IBV-46) was isolated by Dr. R. E. Luginbuhl, Univer­
sity of Connecticut, in July 1951. Hofstad (19) demonstra­
ted that antigenic variation existed among isolates of IBV 
as detected by reciprocal serum neutralization tests. Strain 
33 was originally isolated at New York State Veterinary Col­
lege in 1944. It has since been designated Iowa 33 and con­
sidered to belong to Massachusetts type. Two new serotypes 
were isolated by Dr. M. S. Hofstad, Iowa State University 
and designated Iowa 97 and Iowa 609. Winterfield and Hitch-
ner (20) described the etiology of a new nephritis-nephrosis 
syndrome, associated with infectious bronchitis. Two addi­
tional serotypes were isolated and identified as Gray and 
Holte strains. This new syndrome was confirmed by Cumming 
(21) who had isolated a chicken lethal strain (Australian T) 
of IBV associated with infectious avian nephrosis in Austra­
lia. Winterfield e^ al. (22) described the JMK isolate 
that differed antigenically from those already described for 
nephritis-nephrosis syndrome. Purchase e_t al. (23) grouped 
Gray, Holte and JMK together to form one serotype and added 
chicken embryo lethal orphan virus as the sixth group. 
von Bulow (24) characterized IBV-10 (Cuxhaven) as a sep­
arate serotype, while IBV-7 (Stuttgart) was a variant of 
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Massachusetts type. Hopkins (25) considered there had been 
11 serotypes or variants of IBV described through 1968 when 
he reported on isolation and characterization of SE-17. von 
Bulow (26) recently reported oh a new serotype KA/Koblenz 
isolated from the field. 
Adaptation and Propagation of 
IBV in Cell Cultures 
Fahey (27) and Fahey and Crawley (28) cultivated Conn-
aught Laboratories vaccine strain Rj and the Beaudette embryo 
adapted strain of IBV in stationary flask cultures of frag­
ments of minced chicken embryo kidney, liver and chorioallan­
toic membrane and in monkey kidney cells. Multiplication of 
these 2 Massachusetts type strains was determined by chicken 
embryo infectivity tests. Cytopathic effect was not ob­
served in infected cultures. Earle's "L" cells could not be 
infected. 
Davis (29) attempted to propagate 4 strains of IBV in 
embryonic chicken heart and HeLa cells, without success. 
Buthala and Mathews (30) could not show any cytopathic effect 
with a single passage in primary cultures of chicken embryo 
kidney (CEK) cells. 
Cunningham (31) reported cultivation of IBV in entire 
chorioallantoic membranes in Tyrode's solution with a change 
in pH in infected cultures. Chomiak et al. (32) using 3 IBV 
strains (IBV-31, IBV-46 and Beaudette) found that only the 
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latter caused a clear cytopathic effect on second passage in 
CEK cells. Virus passed in CEK cells caused extensive cyto­
pathic effect in chicken embryo fibroblasts after 8 passages 
in fibroblasts. It was noted that IBV disappeared from the 
fluid in 4 hours, reappeared in 16 hours and reached a max­
imum titer at 48 hours, where it remained for 24 hours, then 
declined. The virus caused cells to shrink or to become 
evenly granular, and the periphery to become very distinct. 
Wright and Sagik (33) demonstrated formation of plaques 
of IBV in CEK cells, thus leading the way for IBV titers to 
be expressed as plaque-forming units, assuming that each 
plaque was formed by one virus particle. 
Pette (34) compared suitability of CEK and chicken 
embryo fibroblasts for propagation of IBV-41, IBV-46 and the 
-Beaudette strains. He found chicken embryo fibroblasts 
superior by 1 log dilution. Both Chomiak et al_. (32). and 
Pette (34) have established that the Beaudette strain causes 
cytopathic effect in cell cultures, but failed to adapt 
other strains. 
Kawamura e^ (35) succeeded in adapting 17 egg pro­
pagated strains isolated in Japan to chicken kidney cells 
derived from chickens 2 to 12 months old. Serotypes of these 
isolates had not been determined. These strains were capable 
of producing cytopathic effect at first or second cell pas­
sage. Attempts to isolate IBV from naturally infected 
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chickens or low egg passages in chicken kidney cells were not 
successful. They were therefore of the opinion that adapta­
tion of IBV to chicken kidney cells required at least 6 to 
10 passages in chicken embryos. 
Mohanty and Chang [36) reported the Beaudette strain 
produced syncytia, usually 48 hours after inoculation of CEK 
cells. Three other Massachusetts type strains did not pro­
duce syncytia, while 2 additional Massachusetts type strains 
did not produce any cytopathic effect. 
Cunningham and Spring (37) indicate that plaque counts 
follow a linear relationship of concentration of virus in 
inoculum and frequency distribution of plaques on replicate 
platings is according to Poisson's distribution, thus indi­
cating single cell infection. Formation of plaques are in­
hibited by specific antiserum. 
Churchill (38) and von Bulow (39) confirmed the opinion 
that IBV had to be adapted to chicken embryos prior to adapta­
tion to chicken kidney or CEK cells. Churchill (38) failed 
to isolate IBV that had undergone successive bird to bird 
passage after 4 blind passages in chicken kidney cells. He 
did note, however, that the Beaudette strain did cause syn­
cytia with a high degree of vacuolation, which underwent 
pyknosis and karyorrhexis. 
Butler (40) failed to recover the Beaudette strain of 
IBV from chicken embryo fibroblasts in excess of amounts 
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inoculated. She attributed the titers to survival of the inoc­
ulum, rather than to any replication. In 3 attempts to pas­
sage IBV in adult fibroblasts, she could not recover virus 
from any of the inoculated cultures 
Infectivity of Cell Culture Propagated 
IBV for Chicken Embryos 
Fahey and Crawley (28) determined IBV replication by in­
oculation of 9-day-old chicken embryos via the chorioallan­
toic sac. Only death of embryos were considered in estima­
ting potency of cell culture fluid. Chomiak et_ al. (32) re­
ported that the Beaudette strain passaged 10 times in CEK 
had a virus titer of 10^* in cell culture and 10^ in embry­
os. They concluded that cell culture propagated virus re­
mained as lethal for embryos as embryo propagated virus. 
Wright and Sagik (33) compared IBV titers as determined by 
plaque count and by egg infectivity. Egg lethal particles 
were calculated by assuming from Poisson's distribution that 
one egg lethal dosegg (ELD^q) equalled 0.7 egg lethal parti­
cles, this has been interpreted that CEK plaque forming units 
are 4 times higher than ELD^q. 
Kawamura e^ (35) found no change in egg infective 
dosegQ (EID50) during 21 passages of IBV in chicken kidney 
cells. Mohanty and Chang (36) stated that infective culture 
fluid of both Beaudette and Wachtel strains had ELD^q titers 
equal to their tissue culture infective dosegg titers. 
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von Bulow (41) found maximal virus titers of lO^-S to 
10^*^ EIDgQ/ml or 10^*® to 10^"^ tissue culture infective 
dosego of IBV propagated in CEK cells for 30 hours, von 
Bulow (39) reports that IBV adapted and propagated in CEK 
cells usually showed higher titers when inoculated into 
chicken embryos than in tissue culture. 
Churchill (38) in comparative titrations of IBV in eggs 
and chicken kidney cells, stated that there did not appear 
to be any marked reduction in sensitivity of the 2 systems. 
Lukert (42) in comparing sensitivity of chicken embryos and 
CEK and chicken embryo liver cells to IBV, stated that his 
results did not agree with Wright and Sagik (33), as he 
found that chicken embryos were 12-40 times more sensitive 
than CEK cells. 
Detection of Intracellular IBV 
by Immunofluorescence 
Stultz (43) using fluorescent antibody techniques, indi­
cated that intracytoplasmic virus in CEK cells were first de­
tectable at about 2 1/2 hours following inoculation. At 12 
hours, cytoplasm of syncytia and infected individual cells 
were completely fluorescent. Mohanty ejt (44) demonstrat­
ed that IBV antigens first appeared in the nucleus, then in 
cytoplasm, in IBV infected CEK cells. Specific nuclear 
staining was detected 7 hours after inoculation, with the 
entire nucleus exhibiting a bright granular fluorescence 
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after 24 hours. By 36 hours IBV antigen was detected in the 
cytoplasm. 
Corstvet and Sadler [45) observed IBV antigens in tra­
cheal smears, thoracic and abdominal air sac epithelial cells 
of chickens infected with egg adapted IBV. The specific 
fluorescence was seen as diffuse granules around the nucleus. 
Braune and Gentry (46) confirmed these latter observations, 
thus refuting those of Mohanty e^ aJ. (44). 
Lukert (47) described relative sensitivity of various 
embryonic chicken cell cultures to IBV. Using immunofluor­
escence the order of sensitivity from highest to lowest was 
kidney, lung, liver and fibroblasts. Appearance of intra­
cellular IBV antigens were first observed at 4 hours in CEK 
cells, while liver cells did not show fluorescence until 6 
hours after inoculation. Conclusions presented for varying 
degrees of sensitivity for liver cells was that only a small 
number of cells are initially infected, while with fibro­
blasts, presence of nonsusceptible cells in higher in propor­
tion to overall cell content, than with other cell types. 
Lukert (48) demonstrated that it is possible to differ­
entiate, though not necessarily identify, IBV serotypes by 
immunofluorescent staining. Conjugates of 3 serotypes 
IBV-41, IBV-46 and Iowa 97 were used in his tests. A combi­
nation of IBV-41 and Iowa 97 (IBV-41/97) conjugate strongly 
stained all IBV serotypes, while using each conjugate 
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separately only slight fluorescence was present. This work 
was supported by Lucio and Hitchner (49) in that only con­
jugates prepared against Iowa 97 and IBV-41 were able to 
stain all strains of IBV used. 
Electron Microscopy of IBV 
Reagan e^ (50) were first to report on observations 
of IBV in the electron microscope. Their preparations were 
centrifuged infected allantoic fluid, with resuspension of 
sediment in distilled water. A small drop of virus suspen­
sion was placed on parlodion film supports, air dried, and 
examined by electron microscope. IBV appeared as round 
bodies, with fine filamentous projections. Size range by 
direct measurement of electron micrograph^ were from 65 to 
135 millimicrons. Reagan and Brueckner (J1) concentrated 
infected allantoic fluid by ultracentrifugation, with resus-
pension of sediment in physiological saline. Following 
clarification of resuspended virus, a sample of supernatant 
fluid was placed on parlodion prepared screens and allowed to 
dry. Sodium chloride was rinsed away and the virus was 
shadowed with chromium. Virus like particles were found to 
have a mean diameter of 70 millimicrons and round heads with 
filamentous projections. Reagan and Brueckner (52) compared 
4 strains of IBV and found their size ranged from 60 to 100 
millimicrons. All samples were shadowed with chromium. 
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Morphology of virus particles ranged from being oblong with 
short projections to round with filamentous projections. 
The first report of IBV-host complex studies, using the 
electron microscope was by Domermuth and Edwards (53). They 
used infected chorioallantoic membrane embedded in methacry-
late, sectioned using a glass knife, and shadowed with chrom­
ium. Some virus particles exhibited a discrete internal 
structure which formed a pattern that suggested the possibil­
ity of a macromolecular arrangement. Doughnut shaped virus 
particles as well as other virus particles which differed 
from one another in opacity to electrons were also evident. 
Berry et al. (5) reported that H. P. Chu demonstrated 
spherical particles in shadowed preparations apparently con­
taining an outer capsule. Berry e;t aj^. (5) and Berry and 
Cruickshank (6) compared 4 IBV strains resembled each other 
in being pleomorphic, but generally circular with diameter 
between 80 to 120 millimicrons. Most but not all particles 
had projections on their surface with a bulbous end mass of 
9 to 10 millimicrons in diameter. Effects of ether, sodium 
dodecyl sulfate, trypsin and neuraminidase on morphology of 
IBV was determined not to be significant. 
Estola and Weckstrom (54) confirmed the work of Berry 
et al. (S) and Berry and Cruickshank (6) that IBV particles 
possess a structure which differs from other viruses. The 
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main difference is projections which are considerably fewer 
than in influenza virus or other known viruses. These pro­
jections are club or pear shaped. Their outlines are vague 
or smudged, but are distributed fairly uniformly around the 
circumference of the virus particle. 
Becker (55) established that IBV replicated in 
the cytoplasm of chorioallantoic membranes by budding into 
cisternae or vesicles. Nazerian and Cunningham (56) con­
firmed that morphogenesis and replication is similar in 
chicken embryo fibroblasts and chorioallantoic membrane 
cultures. 
Immune Response of Chickens 
to Inactivated IBV 
Loss of immunogenic properties following inactivation 
of IBV, using formalin was reported by Delaplane and Stuart 
(57). Hofstad (58) used ultra-violet light to inactivate 2 
strains of IBV, both in an early embryo passage. Chickens 
inoculated with this preparation did not develop immunity. 
Christian and Mack (59) reported that 0.025 percent 
Beta-propiolactone (BPL) was sufficient to destroy the in-
fectivity of a field strain of IBV for chicken embryos when 
allowed to react with infected allantoic fluid for 1 hour. 
Three month old New Hampshire cockerels were inoculated with 
0.5, 1 or 2 ml of inactivated virus, and challenged by intra­
tracheal instillation 19 days later. Nearly twice as many 
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controls were as susceptible to challenge as those birds re­
ceiving 1 or 2 ml of inactivated IBV. No difference was seen 
between controls and those inoculated with 0.5 ml. Inocu­
lated birds had a slight rise in serum neutralizing titers. 
Woernle (60) described an adsorbed formalin (0.2%) in­
activated IBV. He used a second chicken embryo passage of 
chorioallantoic membrane, allantoic-amniotic fluid and liver 
as his source of virus. Evaluation of immunity was by pres­
ence or absence of precipitating serum antibodies following 
intratracheal challenge. His results were inconclusive. 
Berry (61) states that H. P. Chu prepared a BPL inacti­
vated IBV by ultracentrifugation of virus infected allantoic-
amniotic fluid. Immunity was assessed by its ability to pre­
vent a decrease in egg production in infected hens after 
challenge. Berry (61) using a BPL inactivated Massachusetts 
type of IBV mixed with aluminum hydroxide, when inoculated 
intramuscularly into susceptible chickens, induced an anti­
body response similiar to that obtained with live virus , 
Laying hens did not appear to show any depressed egg pro­
duction, as shown by uninoculated susceptible layers exposed 
to a heavy infection with living IBV. Berry (62) reports, 
the duration of neutralizing antibodies remained at a high 
level for up to 56 weeks following 2 inoculations with a 
BPL inactivated IBV at 9 and 16 weeks of age. 
Winterfield (63) in 2 trials of inoculating chickens 
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with a BPL inactivated IBV vaccine used in Great Britain 
failed to stimulate formation of significant neutralizing 
antibodies against IBV-41 and the Beaudette strain. Follow­
ing challenge of immunity, using United States isolates of 
IBV-41, Gray and Holte strains, all chickens examined and 
tested were susceptible to infection and developed respira­
tory signs. 
Swarbrick e^ aJ. (64) studied the effects of egg pro­
duction in 5000 pullets, half of which were inoculated with 
BPL inactivated IBV. There were no significant differences 
between either group. Serum neutralization levels using 
IBV-41 and the Beaudette strain were determined to be non­
significant . 
Box and Barnes (65) reported on using IBV-41 and the 
Beaudette strain to determine antibody levels of chickens 
previously inoculated with BPL inactivated IBV. They ob­
served that sera generally gave a serum neutralization titer 
against the Beaudette strain approximately log^Q 3.0 lower 
than with IBV-41. They recommended that only IBV-41 be used 
to detect field infections. 
McMartin (66) in preliminary investigations reported 
that IBV-41 and the Beaudette strain did not detect any 
appreciable neutralizing antibody response to a commercially 
prepared inactivated IBV of a British Massachusetts type 
isolate. Eleven week old birds were inoculated with 0.5 ml 
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intramuscularly, with a second dose given 4 1/2 weeks later. 
Respiratory tracts were not immunized against challenge with 
IBV-41, while reproductive tracts were partially immunized. 
McDougall [67) described preparation of a BPL inactiva­
ted IBV of low chicken embryo passage. Chickens inoculated 
with 0.5 ml, intramuscularly when 8 weeks of age and again 
when 16 weeks old, demonstrated a level of protection when 
challenged by 3 recent IBV isolates. Serum neutralization 
levels using the Beaudette strain were detected 4 weeks 
following the second injection and persisted for 14 weeks. 
Range of serum neutralization titers was 2.3 to 5.0. No 
significant differences in egg production were noted, how­
ever a few chickens were observed to have mild transient 
symptoms. 
Zanella and Guallini (68) inactivated 3 Massachusetts 
type strains of IBV with formalin. An adjuvant comprised 
of a mixture of Bayol 55 and Arlacel A were added prior to 
intramuscular inoculation. Protection varied with the strain, 
but strain 46/65 isolated in Italy gave good results. 
Brion e^ ^ 1. (69) reports on vaccinating chicks at 5 
weeks of age with 0.5 ml of vaccine, originally described by 
Berry (61), with a second dose given at 8 weeks of age. At 
11 weeks of age, together with unvaccinated controls, they 
were challenged with a French, Massachusetts type isolate. 
Respiratory symptoms were observed in more than 80 percent 
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of both groups. Presence of IBV was confirmed by post-mortem 
and histologic examination and reisolation of virus. 
Hromatka and Raggi (70) recently reported on the effi­
cacy of a commercial BPL inactivated IBV (Iblin) vaccine 
commonly marketed in Great Britain. Following the manufac­
turer's instructions, 17-week-old pullets were administered 
2 doses of 0.5 ml in the breast muscle, 26 days apart. Each 
3.4 
bird was challenged intratracheally with 10 ' EID^g of 
IBV-41. None of the various criteria used to assess suscep­
tibility to IBV such as presence of typical respiratory symp­
toms after challenge, histopathological lesions of the 
trachea, reisolation of challenge virus, and general lack 
of significant serological response revealed any immunity. 
Immune Response of Chickens 
to Live IBV 
Beach (71) was first to report that serum from recov­
ered birds was able to neutralize virus iji vitro and that 
recovered birds were refractory to challenge. Cross immunity 
tests with laryngotracheitis virus and Hemophilus gallinarum 
revealed that immunity for IBV was specific. Beaudette (72) 
stated that for differential diagnosis of respiratory infec­
tions, cross - immunity tests by bird inoculation were reliable 
as a laboratory procedure. These results were later confirmed 
by Delaplane and Stuart (57) who also reported that chal­
lenge with a potent virus 3 weeks following recovery failed to 
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produce the disease. 
Immunizations of chickens was undertaken in 1941 by Van 
Roekel e^ (73) by introducing field strains of IBV to 
growing flocks. Van Roekel et (74) reported that young 
birds inoculated at 6 to 10 weeks of age with a potent virus 
would develop an immunity which would give protection to 
natural exposure during the first laying season. Later, 
Delaplane (75) reported that 10 to 12 days were necessary for 
immunity to develop. It was further suggested that a weak 
virus producing mild but visible symptoms was incapable of 
producing immunity. 
Progeny from flocks immunized (either naturally or arti­
ficially) have naturally acquired passive immunity as was 
first demonstrated by Jungherr and Terrell (76) . In testing 
embryonating eggs from an artificially immunized flock during 
the second half of the incubation period, neutralizing anti­
bodies were found to decline in the yolk with advancing de­
velopment, and to increase concomitantly in the tissues and 
serum of the embryo. In testing chicks from artificially 
and naturally immunized parent stock, both lots were shown 
to maintain antibodies at high levels during the first two 
weeks and to lose them by the fifth week. In field observa­
tions neutralizing antibodies were frequently detected in 
yolk of fresh eggs and serums of asymptomatic brooder chicks 
in territories where IBV was prevalent. However, progeny 
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from immune flocks are not fully protected against the dis­
ease since infections have been observed in chicks approx­
imately a week of age. 
The first large scale experimental immunizations were 
started in 1949 by Jungherr and Luginbuhl (77). IBV was pro­
duced by infecting normal chicks and grinding trachea and 
lungs into a fine suspension. This material was kept frozen 
until administered, either by swabbing the larynx, by intra­
nasal or ocular instillation, or even by spraying virus sus­
pension by means of fly sprayers. Use was made of the fact 
that the disease did not kill older chicks, therefore was 
used only on chicks between 8 to 23 weeks of age. This 
method really amounted to controlled exposure and was effect­
ive in protecting egg producing flocks. As previously noted 
(76) progeny possessed a substantial parental passive 
immunity. 
Hofstad and Kenzy (78) demonstrated that progeny with 
high serum neutralizing titers were susceptible to the dis­
ease under S days of age. Chicks tested at 2 weeks of age 
revealed higher titers than those tested at 1 day and at 3 
weeks after hatching. Four week old chicks had negligible 
titers. It was suggested that complete immunity to the dis­
ease depended on an interaction between tissue immunity and 
circulating antibodies. 
An observation that an immunologic response may be rapid 
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in some birds but not others has been reported by Van Roekel 
et al. (73). In addition they suggested that immunity to 
IBV may decline to such a level of susceptibility that re­
infection may result. However, a majority of flocks that 
have experienced an outbreak of IBV appear to possess ade­
quate immunity for at least 12 months. 
Egg propagated, virulent, IBV-41 was used in Massachu­
setts as an immunizing agent for controlling infectious bron­
chitis. Brandt et al. [79) reported immunity that persisted 
for a year or longer was produced in chickens exposed to 
IBV-41. 
Chicks 3 to 6-weeks-old could not be used in early 
immunization trials, due to virulence of the virus. Crawley 
(80,81) adapted the Connaught strain to chicken e^^ryos, 
which reduced the mortality for chickens between 2 and 20 
weeks of age. Inoculation of completely susceptible birds 
between 1 day and 20 weeks produced immunity which persisted 
for at least 1 to 1 1/2 years. Inoculation of birds beyond 
20 weeks of age is not recommended, due to some observed 
set-backs in egg production. Spray techniques for IBV immu­
nization was recommended, as it reduced labor and time re­
quired for diration of the "take". 
Hofstad (17) reported on ability of 3 different chicken 
embryo passage levels of strain 33 to induce immunity. He 
used resistance to challenge as the criterion for immunity. 
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Chickens aerosol exposed to the 42nd passage had a satisfac­
tory immunity for at least 10 months, while chickens which 
received the 53rd and 67th passage had a lower degree of 
immunity. Beaudette e£ (82) using the 73rd chicken embryo 
passage of virus isolated by them (4) failed to induce immu­
nity in chickens inoculated intramuscularly. Following chal­
lenge all birds exhibited symptoms of IBV. 
Criteria for determining immunity to IBV beyond serum 
neutralization titers and respiratory symptoms were consid­
ered by Chang a]^. (83) . Their final evaluation of proce­
dures was that anyone of the following could be used satis­
factorily: respiratory symptoms, gross pathological lesions 
and histopathological lesions of the trachea, and recovery 
of virus in tracheal exudates and lungs. However, each test 
procedure was of limited value, as it was dependent on time 
of observation, following exposure to IBV. 
Raggi and Lee (84) considered a serum neutralization 
2 titer of 10 or higher as evidence of a specific response to 
IBV. Serum neutralization titers of 10^ or lower was inter­
preted as insignificant and non-specific. Using 3 commercial 
vaccines, they found that a direct relationship occurred be­
tween serum neutralization titers and immune response in 1 of 
the 3 vaccines. However, marked discrepancies existed be­
tween the other 2 vaccines. 
Age and congenital immunity of birds was considered to 
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be a predominating factor in determining length of incuba­
tion period following vaccination by intranasal instillation 
with a commercial IBV preparation by Raggi and Lee (85). 
Susceptible chickens at age 5 days and 2 months showed res­
piratory signs 5 days following vaccination, while 6-day-old 
birds from an IBV immune flock required 8.5 days for the 
appearance of respiratory signs. The median serum neutral­
ization titer of 2 month old birds was 10^ on the 36th day 
post vaccination, while birds 6 days old had a serum neutral­
ization titer of 10^. The 6-day-old chicks from an immune 
flock had decreasing serum neutralizing titers from a pre-
vaccination titer of 10^ to 0 at the 36th post vaccination 
day. 
Some degree of cross protection was found in cross 
immunity studies between Iowa 609, IBV-97 and IBV-46 by 
Hofstad (86). Serum neutralization titers did not agree 
with cross immunity tests. These IBV strains had previously 
been found to be antigenically different by reciprocal serum 
neutralization tests. He observed that tissue immunity of 
respiratory tract mucosa appeared to be an important factor 
in resistance to challenge following recovery from an origin­
al exposure. Hitchner e^ a^. (87) substantiated these re­
sults using cross immunity tests that showed a high degree 
of protection against heterologous strains in absence of a 
significant serologic titer. They also noted failure of one 
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Massachusetts type to protect against another Massachusetts 
type even in presence of a significant serologic titer, which 
demonstrated that there are immunogenic differences among 
serologic types. 
Lukert (88) reported on the reduction of plaques in CEK 
cells to measure IBV neutralizing antibody levels in chicken 
serums. He proposed that a neutralizing index of 1.5 or 
greater would be positive for IBV antibody and an index of 
1.0 to 1.5 would be suspicious. This was based on his 
opinion that plaque reduction methods have at least 2 advan­
tages over virus neutralization tests performed in chicken 
eggs. The former can be completed in 2 days rather than 5 
to 7 days, and serums can be diluted without lowering the 
neutralizing index of the serum. 
Stumpel (89) describes immunity in chickens vaccinated 
at 1 and 4 months of age, that persisted for 43 weeks after 
the second dose. 
Immunity induced in 6-week-old chickens by aerosol 
exposure to a high embryo passage of IBV was discussed by 
Hofstad (90). He studied the response of tracheal mucosa to 
virus challenge over 6-8 months, following initial exposure 
of chickens to high embryo passage IBV. Low virus titers in 
the trachea and lungs of inoculated birds indicated partial 
resistance to challenge. They had eliminated challenge 
virus by 96 hours, whereas, controls still had fairly high 
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virus titers. Resistance appeared to be a type of tissue 
immunity since serum antibody levels were either low or 
negligible. 
Winterfield (91) reported on 3 strains of IBV that are 
or once were used to prepare commercial vaccines. These 
strains were IBV-41, IBV-46 and Ri. Chickens exposed to a 
1:1 mixture of IBV-41 and IBV-46 showed respiratory signs, 
more severe than those birds exposed to each strain singly. 
This combination also gave slightly less protection than 
each did individually. IBV-41 interfered with development 
of IBV-46 antibodies, however, the converse was not observed. 
When IBV-41 was replaced by Rj in combination with IBV-46, 
respiratory signs were also prolonged following challenge. 
Fritsche et (92) compared serum neutralizing titers 
produced by the 52nd and 120th chicken embryo passage of 
their Massachusetts type "H" strain of IBV. Satisfactory 
immunity was produced serologically if H120 were given to 
2-4-week-old-birds and if H52 were administered to the same 
birds at 13 weeks of age. 
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MATERIALS AND METHODS 
IBV Strains Used 
Iowa 53 
Iowa 33 was originally isolated at New York State Veter­
inary College, Ithaca, N.Y., in 1944, and was known as strain 
33. Antigenically it belongs to the Massachusetts type. It 
will be referred to here as IBV-33. This strain was fur­
nished by Dr. M. S. Hofstad, Veterinary Medical Research Insti­
tute, Iowa State University, Ames, Iowa, in various chicken 
embryo passages. Both chicken embryos and CEK cell culture 
passages were used in this work and are so designated when 
the passage number is pertinent. Identification of passage 
levels for all strains, with exception of the strain, Beau-
dette will follow this example: IBV-33-8 indicates the 8th 
chicken embryo passage and IBV-33-46-20 denotes the 20th 
passage in CEK cells of the 46th chicken embryo passage. 
Beaudette 
The chicken embryo lethal, Beaudette strain of IBV was 
supplied by Dr. P. D. Lukert (National Animal Disease Labora­
tory) present address, University of Georgia, Athens, Ga., 
as the 33rd CEK cell passage. The exact chicken embryo pas­
sage number is not known, but has been estimated to be in 
excess of 300. It will be referred to by the Michigan State 
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University Respository number 4 2 .  This strain was origin­
ally isolated by Beaudette and Hudson (4) and comprised one of 
the original Massachusetts types. 
Massachusetts 82828 
This strain of IBV was isolated by Dr. H. Van Roekel, 
at the University of Massachusetts in 1941. It was one of 
the original Massachusetts types. It will be referred to 
herein as IBV-41. IBV-41 was received in the 7th chicken 
embryo passage and adapted to CEK cells in this laboratory. 
Iowa 97 
Iowa 97 was isolated and antigenically characterized by 
Dr. M. S. Hofstad, as a new and separate serotype. This 
strain was received in the 63rd chicken embryo passage, was 
passaged twice in chicken embryos on receipt and adapted to 
CEK cells. Further reference to this strain will be IBV-97. 
Connecticut A5968 
Dr. R. E. Luginbuhl isolated this strain in 1951 from a 
flock at the University of Connecticut. Future reference 
will be made to it as IBV-46. IBV-46 was obtained from Dr. 
P. D. Lukert in the 17th CEK cell passage of the 16th chicken 
embryo passage. 
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Cell Culture and Overlay Media 
Initial culture medium 
Medium 199 in Hanks Base (M-199) was used for initiation 
and maintenance of CEK cell cultures. This formulation is 
the same as that originally proposed by Morgan, Morton and 
Parker (93) and Parker (94), with one exception, the salt 
base of Earle's (95) has been replaced by Hanks base (96). 
M-199 possesses a reduced buffering capacity, thus making it 
more adaptable to CO2 atmosphere incubation. 
One liter of this medium was prepared by combining: 
M-199 (lOX) with glutamine^ 100.0 ml 
NaHCOj 3,5 gms 
Double glass distilled water 
Sterilization was by positive pressure filtration 
2 through a Millipore filter membrane with a pore size of 
0.22j(. Complete medium was prepared by addition of heat in­
activated (56 C for 30 minutes) fetal calf serum at a final 
concentration of 5 percent. All media used in this study 
contained 100 units of penicillin G potassium, 100 mg di-
hydrostreptomycin and 50 units of Mycostatin^. 
^Grand Island Biological Co., Grand Island, N. Y. 
2 
Millipore Filter Corp., Bedford, Mass. 
^Antibiotics, E. H. Squibb § Sons, New York, N. Y. 
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Maintenance medium 
Maintenance medium for adaptation and propagation of 
IBV in CEK cells, consisted of the described M-199 with anti­
biotics and addition of 1 percent fetal calf serum. 
Phosphate buffered saline 
The phosphate basic solution of Dulbecco (97) was used 
for washing tissues cells and preparation of trypsin so­
lution. 
Phosphate buffered saline was prepared as three sep­
arate solutions: 
Solution A: 
NaCl 8.0 gms 
KCl 0.2 gm 
KH2PO4 0.2 gm 
Na2HP04-2H20 2.3 gms 
Double glass distilled water 800.0 ml 
Solution B: 
CaCl2 0.1 gm 
Double glass distilled water 100.0 ml 
Solution C: 
MgCl2 0.1 gm 
Double glass distilled water 100.0 ml 
All chemicals used were of reagent grade. After the 3 
solutions were made up, they were combined, with addition of 
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solution B last to prevent precipitation. The final pH of 
this solution was 7.2-7.4. 
Trypsin solution 
A 0.25 percent trypsin solution was prepared by dissolv­
ing 2.5 gms of 1-300 Trypsin^ in 1 liter of phosphate buf­
fered saline. Sterilization was by Millipore filtration. 
Agar-overlay medium 
Agar-overlay medium for plaque assays was prepared as 2 
solutions : 
Solution A: 
2 lonagar II 
Double glass distilled water 
Solution B: 
M-199 (lOX) with glutamine 
Tryptose phosphate broth^ 
NaCO] (2.8%) 
Double glass distilled water 
Solution A is sterilized at 15 pounds per square inch 
of steam pressure for 15 minutes, and solution B by Millipore 
filtration. Prior to use the agar is melted at 100 C then 
^Nutritional Biochemical Corp., Cleveland, Ohio. 
Consolidated Laboratories, Inc., Chicago, 111. 
^Difco Laboratories, Detroit, Mich. 
2.0 gms 
100.0 ml 
20.0 ml 
28.0 ml 
5.2 ml 
90.0 ml 
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placed along with solution B in a 44 C water bath to equili­
brate, prior to mixing. The addition of 6.0 ml of heat in­
activated fetal calf serum and antibiotics completed this 
medium. 
Neutral red solution 
Neutral red solution was prepared as follows: 
Neutral red^ 0.2 gm 
NaCl 9.0 gms 
Double glass distilled water 1000.0 ml 
NaCl is first dissolved in distilled water, using con­
stant agitation. Neutral red is added to the salt solution 
and stirred continuously for 48 hours. This solution is then 
2 
filtered through a coarse rag filter paper . 
Chicken Embryo Kidney Cell Cultures 
Monolayers of CEK were prepared from kidneys of 18-day-
old chicken embryos. The kidneys were removed as aseptic-
ally as possible, minced into particles of approximately 1 mm 
in size and washed in phosphate buffered saline, to remove 
cellular debris and blood elements. Dispersion of the tis­
sue into cells was accomplished by trypsinization at room 
temperature for 60 minutes. Tryptic digestion was enhanced 
Baltimore Biological Laboratory, Baltimore, Md. 
2 Grade 235, Reeve Angel, Clifton, N. J. 
33 
by continuous agitation, using a teflon covered magnetic bar 
and magnetic stirrer. Cells were collected by pouring the 
trypsin solution containing the dispersed tissue through 
several layers of cheese cloth to remove strands of connec­
tive tissue and undigested tissue. Cells were washed free of 
trypsin by centrifugation at 150 x g at 4 C for 10 minutes. 
The supernatant fluid was decanted and the cells were resus-
pended in phosphate buffered saline. After 2 cycles of cen­
trifugation and washing, the supernatant fluid and red blood 
cells concentrated at the surface of the cell pellet were 
decanted. The CEK cells were resuspended in culture medium 
at a ratio of 1.0 ml of cells to 200 ml of medium. Five ml 
of the cell suspension was dispensed into 60 x 15 mm plastic 
tissue culture dishes^. All inoculated culture dishes were 
incubated at 40 C in an atmosphere of approximately 3 percent 
CO^ in 80-85 percent relative humidity. Cell sheets were 80 
to 100 percent confluent after 20 to 24 hours of incubation. 
All cultures were routinely washed once with phosphate buf­
fered saline to remove any surplus serum, blood cells and 
other debris, prior to use. 
Generally the CEK cells were used following 20 to 24 
hours of incubation. However, in adaptation and propagation 
procedures, some cultures were used at 48 and 72 hours. 
^Falcon Plastics, Los Angeles, Calif. 
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Adaptation of IBV to CEK Cells 
CEK cells were inoculated with 0.5 ml of a 10~ dilu­
tion of the 44th, 89th, 145th and 217th chicken embryo pas­
sage of IBV-33. The virus was allowed to adsorb to the cells 
for 90 minutes at 40 C in a CO2 atmosphere. The inoculum was 
decanted, the cell sheet washed once with phosphate buffered 
saline, and 5 ml of maintenance medium was added. Incubation 
time of inoculated cultures varied from 20 to 26 hours. At 
the conclusion of incubation all cultures were observed for 
cytopathic effect, then placed at -70 C for 30 minutes. 
Freezing and thawing of infected cultures, disrupted cells 
and theoretically released more virus. A sterile silicone 
stopper was used to scrape the cells from the culture plates. 
This process was followed for each passage, with exception of 
stock virus preparations, which was centrifuged at 580 x g 
for 10 minutes at 4 C to remove cells. Stock virus was dis­
pensed in 1 ml amounts and stored at -70 C. 
IBV Propagation in Chicken Embryos 
IBV-33 was obtained in the 6th, 44th, 89th, 145th and 
217th chicken embryo passage. On receipt each was passaged 
twice in 9-day-old chicken embryos by inoculation via the 
~ 2 
allantoic sac with 0.1 ml of a 10 dilution of the previous 
passage. Inoculated eggs were incubated at 37 C for 24 hours 
then chilled at 4 C for 2 hours. Allantoic-amniotic fluid 
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was harvested, pooled and centrifuged for 10 minutes at 580 
X g to remove blood cells and other debris. The supernatant 
fluid was dispensed in 1 ml amounts in vials and stored at 
-70 C. Virus titers were determined by inoculation of 0.1 ml 
of 10 fold dilutions into the allantoic sac of 5 eggs per 
dilution. Inoculated eggs were observed daily for 7 days. 
Deaths, curling, dwarfing and presence of urates in the meso-
nephros of the embryos were used to calculate the EID^^ or 
ELD50. 
Antiserum Preparation 
Antiserum to IBV-33 
Sixty-five, 3-week-old White Leghorn chickens were ex­
posed to an aerosol of 1.0 ml of IBV-33-46 infected allantoic 
amniotic fluid using 10 lbs of air pressure for 5 minutes. 
These chickens received a total of 4 exposures at 7 day in­
tervals. Blood samples were collected from a random sampling 
prior to each exposure. Serums were pooled and assayed for 
virus neutralizing index using the PR-NI method (88). Indi­
vidual serum samples were not tested as only the over-all 
group response to this type of exposure was being considered. 
Four weeks following the initial exposure all chickens were 
exsanguinated. Whole blood was allowed to clot in 200 x 25 
mm culture tubes. Each clot was expressed using a sterile 
stainless steel weight. Serum was collected and clarified 
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by centrifugation at 580 x g for 20 minutes. Serum was dis­
pensed into 10 ml amounts and stored at -70 C. Prior to use 
in the PR-NI test, the antiserum was heat inactivated. 
Antiserum to normal 
chicken globulins 
Normal chicken serum was fractionated 3 times by adding 
saturated ammonium sulfate volume/volume. Excess ammonium 
sulfate was removed from globulins by washing and dialysis 
with physiological saline (0.8% NaCl). Protein nitrogen 
content was determined using the biuret method at 540 thai and 
diluted to a final concentration of 5 mg of protein nitrogen 
per ml. Freunds complete adjuvant was mixed volume/volume 
with the globulins. Two New Zealand while male rabbits were 
injected intramuscularly with 1 ml of the globulin mixture. 
Seven days after the initial injection a series of 4 intra­
venous injections were given at 7 day intervals. Volumes 
injected were 0.5, 0.75, and 1 ml respectively. Two weeks 
following the last injection, the rabbits were exsanguinated, 
serum was collected from clotted blood and stored at -20 C. 
Identification of antibody to normal chicken globulins 
was carried out using agar-gel double diffusion test, after 
the method of Ouchterlony (98) and improved for contrast by 
the agar-gel staining method of Glazier and Fernelius (99) . 
Percipitin lines were obtained against normal chicken serum 
and normal chicken globulins, but not with normal rabbit 
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serum (Fig. 1). 
Preparation of Conjugated Antiserums 
Globulins were obtained from antiserum by dropwise addi­
tion of one volume of saturated ammonium sulfate to 2 vol­
umes of serum. Serum was kept in an ice water bath and con­
stantly agitated during addition of ammonium sulfate. Pre­
cipitated globulins were sedimented by centrifugation for 15 
minutes at 900 x g. Supernatant fluid was discarded and sed­
imented globulins were dissolved in a volume of physiological 
saline that equalled the original serum volume. Fractiona­
tion, sedimentation and dissolving was repeated 2 additional 
times. Final sedimented globulins were dissolved to one half 
of the original serum volume. 
Dissolved globulins were placed in dialysis tubing^ and 
immersed in physiological saline in a Model B Oxford Multi-
pie dialyzer . The dialysis bags were kept in constant mo­
tion to facilitate the dialysis process. This step was to re­
move excess ammonium sulfate. Several changes of physiologi­
cal saline is necessary to complete this process. Presence 
of sulfate ions is checked by mixing equal volumes of the 
dialyzing saline and saturated barium chloride. A precipi­
tate will form in presence of sulfate ions. 
^Visking Co., Union Carbide Corp., New York, N. Y. 
2 
Oxford Laboratories, San Matio, Calif. 
Fig. 1. CTop) Lines of precipitation formed at 24 hours 
between : 
Well no. 
(1) normal chicken globulins 
(2) normal chicken serum 
(3) normal rabbit serum 
(4) antiserum to normal chicken globulins 
(Bottom) Same reaction as above at 48 hours. 
Note fewer lines against chicken globulins than 
against chicken serum. 
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Protein nitrogen content was determined by the biuret 
photospectrometric method at a wavelength of 540 mM using a 
B § L Spectronic 20 spectrophotometer^. Protein nitrogen 
concentration was adjusted to 10 mg/ml. 
Fluoresceinisothiocyanate was dissolved in carbonate-bi­
carbonate solution pH 9. The latter was prepared by dissolv­
ing 5.39 gms of sodium carbonate in 100 ml of distilled water 
and 4.2 gms of sodium bicarbonate in 100 ml of distilled 
water. These solutions should be prepared fresh as needed. 
Addition of 4.4 ml of sodium carbonate to the 100 ml of 
sodium bicarbonate constitutes the carbonate-bicarbonate 
solution. Fluoresceinisothiocyanate was added to dialyzed 
globulins dropwise to obtain a final concentration of 0.25 
rog/mg of protein nitrogen. Dropwise addition of fluores­
ceinisothiocyanate allows for a more even distribution among 
globulin molecules. The above mixture is then placed at 4 C 
overnight, with constant agitation. 
Unconjugated fluoresceinisothiocyanate was removed by 
2 gel filtration through a Sephadex G-25 column. A column 
of 2 cm in diameter and 9-10 inches high is considered nec­
essary to achieve adequate separation of free fluoresceiniso­
thiocyanate and conjugated serum proteins, Sephadex was 
prepared by adding 100 gms to 1 liter of phosphate buffered 
^Bausch and Lomb, Rochester, N.Y. 
2 Pharmacia Fine Chemicals, Piscataway, N.J. 
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saline. 
Adsorption of gel filtered conjugated serum globulins 
with rabbit liver powder for 16 hours at 4 C with constant 
stirring was done to reduce nonspecific staining. Rabbit 
liver powder was made into a slurry by adding 1 gm to 2.5 
ml of phosphate buffered saline. The slurry was added to the 
conjugate to give a final concentration of liver powder of 
20 mg/mg of protein nitrogen. Addition of phosphate buffered 
saline compensated for liquid uptake by liver powder. The 
bulk of rabbit liver powder was removed from the conjugate 
by centrifugation at 900 x g for 20 minutes. The remainder 
was removed by centrifugation at 78,000 x g for 1 hour using 
a #30 rotor in a Model L Untracentrifuge^. Final clarifica­
tion was by filtration through a 0.33^ Millipore membrane 
filter. Conjugate was dispensed in 1 ml amounts and stored 
at -20 C. 
BPL Inactivated IBV-33 
Stock virus of IBV-33-8 was used for Beta-propiolactone 
2 (BPL) inactivation. A dialysis bag containing 200 ml of 
IBV-33-8 was completely immersed in polyethylene glycol-
3 
20,000 (PEG-20M) at 4 C for 18 hours, to concentrate the 
^Bechman Instruments Inc., Palo Alto, Calif. 
2 
Aldrich Chemical Co., Milwaukee, Wise. 
3 
Union Carbide Corp., New York, N. Y. 
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infected allantoic-amniotic fluid. The concentrate was 
brought to a final volume of 50 ml by adding 42 ml of phos­
phate buffered saline. This concentrate when titered in 
7 7 9-day-old chicken embryos possessed a titer of 10 ' EID^g 
per ml. BPL was added to give a final concentration of 
1:2000. IBV-33-8 and BPL were allowed to react for 90 min­
utes at 37 C, while being continuously agitated. A five min­
ute period was allowed for temperature equilibration prior 
to timing BPL inactivation. 
Sterility and inactivation tests were accomplished by 
inoculating twenty 9-day-old chicken embryos with the undi­
luted BPL inactivated IBV via the allantoic sac. Inoculated 
chicken embryos were incubated at 37 C for 7 days, with daily 
observations. No deaths or other pathological effects were 
noted in any of these chicken embryos. 
An inactivated IBV vaccine was prepared by the addition 
of 1 part of aluminum hydroxide^, which contained 2 percent 
aluminum oxide, to 9 parts of BPL inactivated IBV-33. Adju­
vant and inactivated IBV were thoroughly mixed prior to use. 
Immune Response of Chickens 
Chickens used 
Straight-run White Leghorn chickens from an IBV free 
flock maintained at the National Animal Disease Laboratory, 
^Reheis Chemical Co., Chicago, 111. 
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Ames, Iowa, were reared in isolation to 4 weeks of age to 
insure immunologic maturity. Each chicken had been wing 
banded at 1 day of age. 
Challenge procedures 
Eighteen chickens from the original group which had been 
held in separate isolation units and did not possess PR-NX 
for IBV were used as challenge contacts. 
Two chickens were aerosol exposed to 1 ml of IBV-33-8, 
that contained 10^ chicken infective doses. An incubation 
period of 48 hours was allowed, prior to transferring these 
2 birds to the pen containing 16 susceptible chickens. At 
this time typical respiratory symptoms of IBV, such as rales 
were observed. Following a 48 hour incubation period, these 
birds were distributed evenly to cages containing chickens 
previously exposed to CEK adapted and BPL inactivated IBV 
and susceptible controls. Rales were observed in these 
contact challenge birds. 
IBV isolation 
Tissue fragments of comparative size were severed from 
the lungs and kidneys of exsanguinated chickens that had been 
aerosol exposed to CEK adapted IBV and challenged birds. 
Each tissue fragment was minced and suspended in 1 ml of 
tryptose phosphate broth containing 1000 units of penicillin 
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and 1000 mg o£ dihydrostreptomycin. The tracheas were re­
moved and slit longitudinally and the inner surface was 
scraped with a stiff blunt spatula. Scraped cells were sus­
pended in tryptose phosphate broth. Tissue samples were 
ground in a Tenbroeck grinder. Ground tissue was centri-
fuged at 580 x g at 4 C for 15 minutes to remove cell frag­
ments and debris. Supernatant fluid was stored at -70 C. 
CEK exposed Serial 10-fold dilutions of each sample 
were made in tryptose phosphate broth. CEK cells were inoc­
ulated with 0.5 ml of the appropriate dilution and virus was 
allowed to adsorb to the cells for 90 minutes, in a CO2 
atmosphere. The inoculum was then decanted and the cell 
sheet was washed with phosphate buffered saline. An agar-
overlay of 4.5 to 5 ml was applied to each culture. All 
cultures were incubated at 40 C for 44 to 48 hours. Follow­
ing incubation, 5 ml of neutral red was applied to each cul­
ture, and allowed to stand at room temperature for 4 hours. 
Neutral red was decanted and virus plaques enumerated. 
Challenged Virus titers of tissues from challenged 
birds, were done according to the method described under 
IBV propagation in chicken embryos. 
Tissue smears 
Tissue smears were made of the freshly harvested lung 
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and kidney, and scrapings o£ the tracheal epithelium. This 
was accomplished by placing tissue between 2 clean microscope 
slides and rotating their surfaces together, with enough 
pressure to ensure an even distribution of tissue cells. 
Preparations were air dried at room temperature. Fixation 
was by immersion of preparations in a mixture of 4:1 acetone-
methanol for 10 minutes at 4 C. If the slides were not 
stained with conjugated antiserum, immediately, they were 
stored at -20 C. 
Conjugate staining and 
examination 
Fixed tissue smears were stained with conjugated anti­
serum for 1 hour at room temperature in a humid chamber. 
Conjugate was removed by washing with phosphate buffered 
saline. Stained preparations were then immersed in a swirl­
ing bath of phosphate buffered saline for 15 minutes, with 
changes of saline every 5 minutes. A final rinse with dis­
tilled water was followed by air drying at room temperature. 
A cover glass was mounted over each preparation using phos­
phate buffered saline-glycerin (1:9). Stained preparations 
were examined for specific fluorescence using a Leitz Ortho-
lux^ microscope equipped with a dark field condenser, BG-38 
heat filter, UG-12 exciter filter and an OG-1 barrier fil­
ter. Illumination was by an Osram HBO-200 Mercury burner. 
^E. Leitz, New York, N.Y. 
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Immune response to BPL 
inactivated IBV-73" 
Forty 4-week-old chickens were divided into equal 
groups. Three groups were to be exposed to BPL inactivated 
IBV-33 either by aerosol or inoculation or both. The fourth 
group would serve as unexposed controls. Blood samples were 
collected from randomly selected birds to determine their 
serologic status, prior to exposure. 
Two groups of birds were aerosol exposed to 4 ml of the 
BPL inactivated IBV, using a #40 De Vilbiss nebulizer^ under 
4 lbs of air pressure. This nebulizer has been referenced 
by Markham et [100] to dispense droplets in the range of 
0.5 to 1 micron in size, that will penetrate deeply into the 
respiratory tract. During exposure all birds were kept in 
motion, by knocking on the sides of the units. A second 
aerosol exposure was administered 4 weeks later. 
One group of aerosoled birds and the third group were 
inoculated subcutaneously in the neck region with 0.5 ml of 
BPL inactivated IBV vaccine. The neck region was selected 
for 2 reasons: (1) less economic loss if the adjuvant was not 
assimilated and (2) a good supply of lymphatic tissue is pre­
sent in this area. A second inoculation was given 4 weeks 
later. 
Individual serum samples were obtained from birds in 
^The De Vilbiss Co., Somerset, Pa. 
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the 4 groups at 2, 4, 6, and 10 weeks following initial aer­
osol and or inoculation. These were used to study individ­
ual bird serologic response to inactivated IBV-33. Individ­
ual serum samples of each group were pooled and tested for 
cross reactivity to other Massachusetts type strains [IBV-41, 
and IBV-42) as well as other serotypes as IBV-46 and IBV-97. 
All strains used in these tests had been adapted to CEK 
cells. 
All 4 groups of birds were challenged at the end of 10 
weeks, by contact exposure as described. Two birds of each 
group were exsanguinated at 24 hour intervals for 4 days to 
evaluate the degree of protection induced by BPL inactivated 
IBV-33. Virus isolation and identification were carried 
out as described. 
Immune response to 
CEK adapted IBV 
Four groups of 25 birds each were used to test invasive­
ness and immunogenicity of CEK adapted IBV, administered via 
aerosol exposure. Each group was subdivided and placed in 
the outer cages of a 9 cage isolation unit. This type of 
unit is illustrated in Fig. 2, however, only 6 cages appear 
in this figure, an additional stack of 3 cages was added for 
these experiments. A fifth group of 12 birds was placed in 
the center cage to test effectiveness of these isolation 
Fig. 2. Typical construction of isolation units used in 
this study. An additional stack of 3 cages were 
added for these experiments. 
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units to hold aerosoled inoculum. These isolation units were 
kept at a negative pressure in respect to room environment. 
This is designed to prevent contaminated air escaping into 
the room and entering other isolation units. Each cage re­
ceives air through individual intakes, equipped with dust 
filters. Individual cage air outlets are funneled into a 
common duct (Fig. 3), containing an air pressure regulated 
roll-screen filter. All air from the cages is exhausted to 
the outside atmosphere. Water supply lines to each cage are 
equipped with a back-flow valve. Drinking water taps are 
allowed to flow continuously. Effluent pipes are equipped 
with an "S" trap which is kept filled with run-off from the 
drinking water taps. This latter prevents contaminants 
entering the units through the sewage system. 
Blood was collected from randomly selected birds to 
determine serologic immune status. Each test group was aer­
osol exposed to a different stock virus of CEK adapted 
IBV-33 (Fig. 4). Fifteen minutes were required to aerosol 
1 ml of stock virus using a #40 De Vilbiss nebulizer, under 
4 lbs of air pressure. A second exposure was administered 
4 weeks later. 
Two birds of each group were exsanguinated at 48 and 
96 hours after each exposure. Tissue smears and samples for 
virus isolation and intracellular IBV antigens detectable 
by immunofluorescence were harvested from each bird. One 
Fig. 3. Individual air ducts, leading to a common exhaust 
system. 

Fig. 4. Isolation unit arrangement containing birds 
aerosol exposed to CEK adapted IBV-33 and 
controls. 
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33-89-20 33-46-20 33-46-20 
33-147-20 Controls 33-89-20 
33-217-20 33-147-20 33-217-20 
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control bird was exsanguinated at 96 hours after the second 
aerosol exposure, with tissue smears and samples being taken. 
Individual blood samples were collected 2, 4, 6, 10, 
and 12 weeks post initial exposure to test serologic response 
to CEK adapted IBV and challenge virus. 
All 5 groups were challenged on the 10th week by con­
tact exposure as described. Two birds were exsanguinated at 
24 hour intervals for 4 days following challenge. Tissue 
smears and samples were obtained for virus isolation and 
identification of intracellular IBV antigens and intracellu­
lar globulins by immunofluorescence. 
Determination of immunity 
Immunity was determined by the induction of serum 
neutralizing antibodies with a PR-NI titer of 1.5 or greater, 
absence of clinical respiratory symptoms, and failure to 
isolate virus from selected tissues following challenge. 
IBV titers of 10^ ELD50 or lower obtained by chicken embryo 
inoculation using tissue samples of challenged birds are 
considered to be negative. Virus titers at this level are 
dependent on observation of pathologic lesions in 1 or 2 
of 5 embryos inoculated. 
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Negative Staining for 
Electron Microscopy 
IBV-33 was cultivated in chicken embryos (9th passage), 
and in CEK cells (33-46-20) as described previously. 
Allantoic-amniotic fluid was harvested 36 hours and cell 
culture fluid 24 hours after inoculation. Both IBV con­
taining allantoic-amniotic fluid and cell culture fluid 
were clarified from cell debris at 16,300 x g for S minutes 
1 
using a HB-4 head in a Sorvall RC-1 refrigerated centri­
fuge. Supernatants were then ultracentrifuged at 64,000 
X g for 45 minutes using a swinging bucket type SW 25.1 
2 
rotor in a L-2-50 Ultracentrifuge . Pellets were resus-
pended by magnetic stirring in distilled water. 
Preparations were negatively stained for electron 
microscopic examination with neutralized phosphotungstic 
acid using minor modifications of the Brenner and Home 
(101) method. A drop of particle preparation was added to 
a spot plate well containing 3-4 drops of 4 percent phospho­
tungstic acid, 15-20 drops of water and 1-2 drops of a 
freshly prepared bovine serum albumin solution (ca. 0.1% 
Cohn's fraction 5). After mixing the preparations were 
sprayed on carbon-coated collodion-filmed grids with a 
^Ivan Sorvall Inc., Norwalk, Conn. 
2 
Beckman Instruments Ins., Palo Alto, Calif. 
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Vaponefrin all-glass nebulizer^. Grids were examined 
2 immediately in a Phillips EM-200 electron microscope 
operated at 60 KV with double condenser illumination and 
a 20-25 micron foil aperture in the objective lens. 
^Vaponefrin Co., New York, N.Y. 
^Phillips Scientific Equipment, Eindhoven, Netherlands. 
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RESULTS 
Adaptation and Propagation 
of IBV-33 in CEK Cells 
Response of CEK cells to inoculation with egg propaga­
ted IBV-strain 33 at various passage levels is shown in Table 
1. Cytopathic effect was observed on the first passage, 
within 24 hours after inoculation. Cytopathic effect was 
progressively intensified with each passage in CEK cells. 
IBV-33-217 required 16 passages before producing cytopathic 
effect as intense as that produced by 33-46 in third passage. 
The first noticable change generally occurred about 12-14 
hours after inoculation. Between 16-18 hours, infected cells 
were observed to have cytoplasmic granules, which were not 
found in uninoculated control cells. Clumping of cells was 
accompanied by shrinking and vacuolization between 20-24 
hours followed by cell detachment. 
Average IBV titers obtained by successive passage in 
CEK cells, varied from 10^'^ PFU/ML for 33-46 to 10^*^ 
PFU/ML for 33-217, even though the ELDgg of the original in­
oculum of 33-46 (10^'^) and 33-217 (10^*^) was similar. 
Virus titers of 33-217 had greater fluctuations between pas­
sages than those of the other 3 egg passages,. There were 4 
instances where there was a rise or decline in excess of 
1 logio* These occurred at the 8th, 9th, 14th and 19th 
passage. 
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Table 1. Adaptation and propagation of 4 egg passage levels 
of IBV-33 in CEK cells. 
Passage Egg passage level of original inoculum 
level in 46 89 147 217 
CEK cells PFU CPE PFU CPE PFU CPE PEU CPE 
1 7.3 s^ 7.9 s 7.6 s 6.3 s 
2 7.2 s 7.5 s 7 . 2  s 6.3 s 
3 6.8 g 7.1 f 6.8 s 5.7 s 
4 7.4 g 7.2 f 7.1 s 5.5 s 
5 7.0 g 7.1 f 6 . 7  s 6.0 s 
6 7.2 g 7.1 f 7 . 0  s 5.4 s 
7 7.7 g 7.9 f 7.3 f 5.7 s 
8 7.7 g 7.6 g 7.4 f 7.0 s 
9 7.6 g 7.8 g 7.4 f 5.5 s 
10 7,8 g 6.5 g 6.8 g 6.4 s 
11 7 . 8  g 6.3 g 6.4 g 6.9 s 
12 7.6 g 6 . 3  g 6.6 g 7.2 s 
13 7.5 g 6.8 g 6.9 g 6.4 s 
14 7.7 g 7.5 g 7.1 g 5.7 f 
15 7.7 g 6.9 g 7.8 g 6.9 f 
16 7.6 g 6.0 g 6.0 g 7.3 g 
17 7 . 3  g 6.4 g 6.7 g 7.0 g 
18 7.6 g 7.2 g 7.8 g 6.8 g 
^s = slight, f = fair, g = good. 
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Table 1. (continued) 
Passage Egg passage level of original inoculum 
level in 46 89 147 217 
CEK cells PFU CPE PFU CPE PFU CPE PFU CPE 
19 7.8 g 7.1 g 7.6 g 5.5 g 
20 6.5 g 5.3 g 5.8 g 6.3 g 
Average 7.3 7.0 7.0 6.3 
Infectivity of CEK Propagated 
IBV-33 for Chicken Embryos 
Infectivity of CEK adapted IBV-33 for chicken embryos 
were examined during 20 passages (Table 2) . The ELDgg of 
33-46 did not undergo any significant changes, from that of 
the original inoculum (10^*®), during the 20 passages in CEK 
cells. The ELD50 of 33-46 exceeded or equalled (12th pas­
sage) the PFU titer for the 20 CEK passages. The virus 
titer of 33-89 used as inoculum was 10^*^ ELDgg. An ELD^q 
of 10^'^ to 10^'^ was obtained for the first 10 CEK passages. 
Virus titers ranged from 10^ to 10^*^ ELD50 for the re­
maining passages except for the 18th, where the titer was 
8.0 
10 * ELDgQ. The ELD50 titers exceeded the PFU titers in 
all 20 passages. 
8 5 
IBV-33-147 had a 10 ' ELD50 when used as inoculum for 
the first CEK passage. Virus titers of 10®*® to 10^*^ ELD50 
Table 
Passag 
level 
CEK ce 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
2 0  
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Infectivity of CEK propagated IBV-33 for chicken 
embryos. 
Egg passage level of original inoculum 
46 g"g 
PFÛ EID^q EID^q/PFU PFU ËÏD%^ EIDgg/PFU 
7.3 7.7 .4 7.9 8.8 .9 
7.2 7 . 8  .6 7.5 8.5 1.0 
6.8 7.6 .8 7.1 8 . 2  1.1 
7.4 8 . 4  1.0 7.2 8.5 1.3 
7.0 7 . 8  .8 7.1 8 . 2  1.1 
7.2 7.6 .4 7.1 8 . 2  1.1 
7.7 8.5 .8 7.9 8 . 8  .9 
7.7 8.5 .8 7.6 8 . 8  1.2 
7.7 7.8 .1 7.8 8.6 .8 
7.6 7.7 .1 6.5 8.0 1.5 
00
 
8.6 .8 6.3 7.0 .7 
7.8 7.8 .0 6.3 7.0 .7 
7.6 8.5 .9 6.8 7.5 .7 
7.5 8.6 1.1 7.5 7.8 .3 
7.7 8 . 2  .5 6.9 7.3 .4 
7.7 8.4 .7 6.0 6.7 .7 
7.6 8.7 1.1 6.4 7.2 .8 
7.3 8.0 .7 7.2 8.0 .8 
00 
8.5 .7 7.1 7.8 .7 
6.5 7.8 1.3 5.3 6.4 1.1 
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Table 2. (continued) 
Passage Egg passage level of original inoculum 
level in m7 2T7 
CEK cells PFU EIDgg EID50/PFU PFU EID50 EID50/PFU 
1 7.6 
00 
.6 6.3 7.5 1.2 
2 7.2 8 . 3  .7 6 . 3  7.6 1.3 
3 6.8 8.0 1.2 5.7 7.2 1.6 
4 7.1 7 . 4  .3 5.5 6.5 1.0 
5 6.7 7.2 .5 6.0 6.3 .3 
6 7.0 7.5 .5 5.4 6 . 0  .6 
7 7.3 8.2 .9 5.7 6.5 .8 
8 7.4 7 . 3  - .1 7.0 6.7 -.3 
9 7.4 7.8 .4 5.5 7.3 1.8 
10 6.8 6.8 .0 6.4 7.2 .8 
11 6.4 6.3 -.1 6.9 7 . 8  .9 
12 6.6 7.5 .9 7.2 7 . 6  .4 
13 6.9 7.2 .3 6.4 6.8 .4 
14 7.1 6.5 -.6 5.7 6.5 .8 
15 7.8 6.6 -1.2 6.9 6.5 -.4 
16 6.0 6.3 .3 7.3 6.5 - .9 
17 6.7 6.8 .1 7.0 6.3 - .7 
18 7.8 7.8 .0 6.8 6.4 -.4 
19 7.6 7.3 - .3 5.5 6.6 1.1 
20 5.8 6.8 1.0 6.3 6.6 .3 
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were obtained for the first 3 and the 7th CEK passage. The 
7 8 
remaining passages had ELD50 titers that ranged from 10 
to 10^'^. The PFU titers exceeded the ELD50 titers in the 
8th, 11th, 14th, 15th, and 19th passages. 
IBV-33-217 did not have any sudden changes in virus 
titers (ELD50) during the 20 CEK passages. An inoculum 
7 8 
containing 10 * ELD50 was used for the first passage. 
Virus titers of 33-217 for the 20 passages did not vary more 
than 10^*^ ELD5Q. PFU titers exceeded ELD^q titers in the 
8th and 15-18th passages. 
Immune Response of Chickens 
to BPL Inactivated IBV 
Serologic response 
Chickens given 2 aerosol exposures 4 weeks apart of in­
activated IBV-33 failed to respond as indicated by negative 
PR-NI results (Table 3). 
A second group of birds given 2 aerosol exposures of 
the above preparation and 2 subcutaneous inoculations of 
BPL-IBV vaccine, responded satisfactorily, with all birds 
being positive or having a PR-NI titer in excess of 1.5 at 
6 weeks. When tested at 2 weeks there were 3 (no. 5052, 
5396, 5050) partials with PR-NI titers between 1.0-1.5 and 
2 positives (no. 5444, 5503). On testing at 4 weeks, 6 pos­
itives and 1 partial (no. 5369) were detected in 9 birds. 
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Table 3. Serologic response of chickens to 2 aerosol 
exposures and/or subcutaneous inoculations of BPL 
inactivated IBV-33. 
Type of Bird Time in weeks following initial exposure 
exposure no. 2 4 6 10 
Aerosol 5045 
a 
0.0 0.1 0.1 0.0 
5228 0.0 0.0 0 . 3  0.0 
5239 0.3 0.0 0.4 0 . 3  
5075 0.2 0.4 0 . 2  0.0 
5342 0.0 0.2 0.4 0.0 
5417 0.2 0.3 0.5 0.0 
5048 0.2 0.2 0.6 0.0 
5072 0.0 0.1 0.4 0.0 
5411 0.2 0.1 0.2 0.0 
5461 0.0 0.0 0.3 0.0 
Aerosol and 5067 0.9 1.6 3 . 5  3.5 
inoculated 
5444 2.4 2 . 3  3.6 3 . 6  
5230 0.5 2 . 8  3.1 2.7 
5052 1.2 1.9 3.5 3.2 
5255 0.8 2.9 3 . 8  3 . 8  
5503 1.8 
b 
D 
5044 0.4 0.6 3.5 3.3 
5396 0.3 0.9 3.5 3.5 
5369 1.0 1.3 3.7 3 . 4  
Indicates a negative virus titer 
D =dead since last test 
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Table 3, (continued) 
Type of Bird Time in weeks following initial exposure 
exposure no. 2 4 5 TO 
Aerosol and 
inoculated 5050 
Inoculated 
Controls 
5454 
5036 
5234 
5504 
5518 
5402 
5253 
5425 
5431 
5245 
5125 
5109 
5419 
5046 
5235 
5247 
5455 
5189 
1.2 
0.9 
1 . 2  
0 . 6  
0.9 
1 . 1  
1 . 1  
0 . 0  
0.4 
1.9 
1.5 
0 . 2  
0 . 0  
0 . 0  
0 . 0  
0 . 0  
0 . 0  
0 . 0  
0.1 
3.3 
0 . 6  
0 . 8  
0.9 
1 . 6  
1.4 
1 . 2  
0 . 2  
1.4 
1.3 
1.5 
0 . 0  
0 . 0  
0 . 1  
0 . 0  
0 . 0  
0 . 2  
0 . 1  
0 . 0  
3.9 
3.6 
3 . 6  
3.3 
3.5 
3.6 
3.7 
1.4 
4.0 
3.5 
3.8 
0.4 
0 . 2  
0 . 2  
0.3 
0 . 1  
0 . 2  
0 . 2  
3.7 
2.4 
2 . 6  
2 . 1  
1 . 8  
3.5 
3.2 
0 . 1  
3.4 
2 . 8  
3.6 
D 
0 , 0  
0 . 0  
0 . 0  
0 . 0  
0 . 0  
0 . 0  
= killed since the last test. 
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Table 3. (continued) 
Type of 
exposure 
Bird 
no. 
Time in weeks following initial exposure 
2 4 6 10 
Controls 5432 0.1 0.1 0.5 0.0 
5058 0.2 0.2 0.3 0.0 
5227 0.3 0.1 0.3 0.0 
5485 0.0 0.0 0.1 0.0 
One bird (no. 5503) originally found to be positive had died 
prior to the 4 weeks test. All birds had significant PR-NI 
titers, with an average of 3.56 at 6 weeks. These titers 
were maintained at near this average (3.41) until challenged 
at 10 weeks. 
A third group of chickens which were inoculated sub-
cutaneously with 2 doses of BPL-IBV vaccine were slow in 
responding serologically. Serum samples collected at 2 
weeks, indicated 3 partials (no. 5036, 5518, 5402) and 2 
positives (no. 5431, 5245). Testing at 4 weeks indicated 4 
partials and 2 positives (no. 5504, 5245), however, only one 
of the latter was positive (no. 5245) during the 2 weeks test. 
The second positive (no. 5431) at 2 weeks, had a titer that 
dropped to a negative status. Six weeks tests indicated 9 
of 10 birds had PR-NI titers that equalled those of the group 
that were given both aerosol exposure and subcutaneous 
67 
inoculations. One bird (no. 5253) did not respond beyond the 
partial level during the period of observation. At 6 weeks 
the average PR-NI titer of this group was 3.4, this average 
declined to 2.9 when tested at 10 weeks. 
Control birds remained negative during the period of 
observation. 
Neutralizing indices of pooled 
sera to _5 strains of IBV 
Virus neutralization tests were preformed in CEK cells 
to determine the PR-NI titers of pooled serum of chickens 
previously immunized with BPL inactivated IBV-33. IBV 
strains used as antigen were 3 Massachusetts types (IBV-33, 
IBV-41, IBV-42), IBV-97 and IBV-46 (Table 4). 
Pooled sera obtained from an initial bleeding of a ran­
dom group of birds, prior to commencing these experiments 
had negative PR-NI titers to the 5 IBV strains. Serum sam­
ples obtained at 2 weeks, were not tested, due to their low 
individual PR-NI titers, for the homologous strain. 
Chickens which received 2 aerosol exposures of inacti­
vated IBV-33 and control birds were considered to be nega­
tive to the 5 IBV strains. 
Chickens that received an initial aerosol exposure and 
subcutaneous inoculation of inactivated IBV-33, had a PR-NI 
titer of 2.0 to IBV-33, when tested at 4 weeks. Negative 
titers were recorded for the other 4 strains. The 6 week 
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Table 4. PR-NI titers of pooled sera of chickens aerosol 
exposed and/or inoculated with BPL inactivated 
IBV-33, to 3 IBV serotypes. 
IBV 
Serotype 
Date 
serum ^ 
collected 
Type of exposure 
Aerosol Aerosol/ 
inoculated 
Inoculated Controls 
33-46-20 4b 0.3 2.0 1.9 0.1 
6 0.5 4.2 4.0 0.4 
10 0.5 3.9 3.7 0.4 
41-7-10 4 0.8 0.4 1.8 0.7 
6 0.7 3.0 3 . 2  0.6 
10 0.8 3.7 2.7 0.8 
42-7-34 4 0.1 0.5 1.0 0.1 
6 0.8 4.9 4.8 0.7 
10 0.0 3.6 3.4 0.0 
97-65-11 4 0.0 0.0 0.3 0.0 
6 0.3 1.5 1.5 0.0 
10 0.0 0.9 1.0 0.0 
46-16-17 4 0.3 1.0 0.6 1.0 
6 0.2 2 . 2  2.2 0.2 
10 1.0 1.0 0.9 1.0 
^Time in weeks following initial exposure. 
^Time of second exposure. 
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tests were conducted 2 weeks following the second aerosol 
exposure and subcutaneous inoculation. The following PR-NI 
titers were obtained for each strain; 4.2 CIBV-33); 3,0 
CIBV-41); 4.9 (IBV-42); 1.5 ClBV-97) and 2.2 CIBV-46). PR-NI 
titers obtained for the 3 Massachusetts types are more sig­
nificant than for the 2 heterologous serotypes. Pooled 
serum samples tested at time of challenge (10 weeks) had the 
following PR-NI titers: 3.9CIBV-33); 3.7 (IBV-41) and 3.6 
(IBV-42). PR-NI titers to the 2 heterologous serotypes had 
dropped below the significant level. 
Subcutaneously inoculated chickens had PR-NI titers 
that resembled those described for the above group. The 
only notable difference, being the appearance of a PR-NI 
titer of 1.8 to IBV-41 at 4 weeks. 
Response to challenge 
Inactivated IBV-33 failed to induce an immune response 
in tracheal epithelium, when given via aerosol exposure. 
Virus was isolated from all tracheal samples following chal­
lenge (Table 5). Respiratory involvement was first observed 
48 hours after challenge. These signs consisted of gurgling 
and wheezing, which lasted for several days. Intracellular 
IBV antigens as demonstrated by immunofluorescence as ob­
served in the cytoplasm of single cells of tracheal smears 
(Fig. 5). IBV titers in 6 of 8 lung samples equalled those 
found in the tracheal samples. Two lung samples were 
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Table 5. Detection of virus in selected tissues of chickens 
immunized with BPL inactivated IBV-33 and challeng­
ed 6 weeks later with the same strain, using immu­
nofluorescence and chicken embryo inoculation. 
Type of 
exposure 
Bird 
no. 
Hours 
after 
challenge 
Trachea 
EID50 FA 
Tissue 
Lung 
EID50 FA 
Kidney 
EID50 FA 
Aerosol 5239 24 3.3 0.0 - 1.2 
5461 3.4 2.2 0.6 
5075 48 >3.5 + 3.4 + 0.6 
5417 2.8 0.0 0.0 
5045 72 3.3 + 3.4 - 0.0 
5048 3.3 3.0 0.8 
5072 96 >3.5 + 3.4 - 1.7 
5228 3.3 2.8 0.6 
Aerosol and 5444 24 0.0 - 0.0 - 0.6 
inoculated 
5050 0.8 1.2 0.7 
5067 48 2.7 + 0.6 - 0.8 
5255 0.0 0.8 0.0 
5230 72 0.2 + 0.0 - 0.8 
5397 2.0 1.2 0.6 
5044 96 3.3 + 1.7 - 0.0 
5369 3.4 1.2 0.0 
Inoculated 5402 24 3.3 - 0.0 - 0.6 
5425 0.6 0.0 0.0 
(-) Negative, (+) Positive. 
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Table 5. (continued) 
Type of Bird Hours Tissue 
exposure no. after Trachea Lung Kidney 
Challenge BiDsO FA EIDso FA EID50 FA 
Inoculated 5454 48 3.4 + 3.0 - 0.0 
5518 2.7 1.5 0.9 
5504 72 2.4 + 3.3 - 0.8 
5253 1.4 1.2 0.7 
5036 96 >3.5 + 3.4 - 1.0 
5234 2.7 1.5 0.8 
Controls 5109 24 3.3 + 1.5 - 3.0 
5058 3.4 3.2 1.2 
5235 48 >3.5 + >3.5 - 2.2 
5247 3.0 3.2 0.0 
5189 72 >3.5 + 3.4 - 2.0 
5432 3.4 3.4 2.5 
5227 96 3.4 + 2.5 - 3.4 
5046 >3.5 >3.5 3.2 
Fig. 5. Fluorescent antibody staining of trachea smear 
48 hours post challenge from bird immunized via 
aerosol exposure with inactivated IBV. Note 
intense staining and antigen completely filling 
the cytoplasmic area of the cell. (X250). 
Fig. 6. Fluorescent antibody staining of trachea smear 
48 hours post challenge from bird immunized by 
aerosol exposure and subcutaneous inoculation with 
inactivated IBV. The amount of antigen in the 
cytoplasm varies from a few particles to a 
compactly filled cell. (X250). 
Fig. 7. Fluorescent antibody staining of trachea smear 
48 hours post challenge from a control. Many 
cells are seen with antigen filling the cyto­
plasm. CX250). 
Fig. 8. Fluorescent antibody staining of trachea smear 
48 hours post challenge from a bird immunized 
via aerosol exposure to 33-46-20. Two intensely 
stained cells are present. (X250). 
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negative. Intracellular IBV antigens were only observed in 48 
hour lung samples. Two (no. 5239, 5072) of 8 kidney samples 
yielded virus of low titer, but no intracellular antigens 
were present. 
BPL inactivated IBV-33 given simultaneously as an aero­
sol and subcutaneous inoculation as an immunizing agent, pro­
tected the tracheal epithelium of 50 percent of the birds 
(Table 5). Two (no. 5044, 5369) of the 4 positives were col­
lected 96 hours following challenge. Respiratory signs were 
observed in all birds, from which tissue samples were ob­
tained. Intracellular IBV antigens were observed at 48 hours 
after challenge and then only in tracheal smears. These anti­
gens appeared in the cytoplasm as diffusely spread granules, 
to compact fluorescent masses (Fig. 6). Virus was isolated 
from 4 of 8 lung samples, in one (no. 5050) the tracheal 
sample failed to yield virus. All kidney samples were 
negative. 
Immunizations by subcutaneous inoculations of inactiva­
ted IBV-33 failed to protect tracheal epithelium, as virus 
was isolated from 7 of 8 samples. Respiratory signs persist­
ing for several days, were present in all birds sampled. 
Intracellular IBV antigens resembled those observed in the 
previous group. Lung and kidney smears were immunofluores-
cent negative. 
Isolation of virus from tissues of control birds was 
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successful in all instances, with exception of one kidney 
sample (no. 5247). Intracellular IBV antigens were detected 
at 24 hours after challenge in all tracheal smears, with 
lung and kidney smears being negative. Fig. 7. is repre­
sentative of the positive tracheal smears obtained using 
immunofluorescence. 
Immune Response of Chickens 
to CEK Adapted IBV 
Isolation of virus 
in CEK celli" 
Tracheal smears from susceptible chickens given one 
aerosol exposure of CEK adapted IBV-33 contained at least 
n Q 
10 PFU/ML of virus at 48 and 96 hours after exposure 
(Table 6). Penetration of CEK adapted IBV into other organs 
under observation were variable, with all lung samples of 
birds exposed to 33-46-20 yielding virus and those exposed 
to 33-217-20 being negative. Kidney samples did not yield 
any virus. 
Tissue samples collected at the same time intervals 
(Table 6) following the second aerosol exposure to CEK adapt­
ed IBV-33 were negative for virus, with one exception, bird 
no. 5362, the tracheal sample yielded virus, with a titer of 
10^'^ PFU/ML 
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Table 6. Use of immunofluorescence and CEK cell inoculation 
to detect the presence of IBV in selected tissues 
of chickens following 2 aerosol exposures to CEK 
adapted IBV-33. 
Passage Bird Exposure Hours Tissue 
level no. no. after Trachea Lung Kidney 
exposure PFU FA PFU FA PFU FA 
33-46-20 5086 I 48 3.0 o
 
00
 
5250 2,2 + 0.3 
5371 96 2.8 + 2.7 
5395 3.6 o
 
00
 
5090 II 48 - - -
5249 - - -
5192 96 - - -
5268 - - -
33-89-20 5260 I 48 3.1 + -
5399 2.0 + -
5514 96 0,9 + 0.8 
5256 1.0 + 0.6 
5488 II 48 - - -
5252 - - -
5407 96 - - -
5069 - - -
33-147-20 5066 I 48 3,7 + 1.6 
5251 3,1 + -
^ (-) Negative, (+) Positive . 
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Table 6. (continued) 
Passage 
level 
Bird 
no. 
•Exposure 
no. 
Hours 
after 
exposure 
Trachea 
PFU FA 
Tissue 
Lung 
PFU FA 
Kidney 
PFU FA 
33-147-20 5241 I 96 2.7 + + 
cn o
 — -
5054 1.8 + 2.0 + — -
5348 II 48 - - - - -
5242 - - - - - -
5095 96 - - - - -
5481 - - - — -
33-217-20 NT^ I 48 3.7 + - - - -
5029 3.2 + - - - -
5259 96 2.5 + — - - -
5257 1.7 + - - - -
5467 II 48 - - - - -
5362 2.2 - — - - -
5232 96 - — - - -
5470 - - — - - -
Control 5419 - - - - -
^NT = no tag on this bird. 
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Intracellular IBV antigens 
of CEK adapted IBV 
Intracellular IBV antigens were detected in tracheal 
0 9 
and lung smears that had a virus titer of 10 ' PFU/ML or 
greater, following the first aerosol exposure to CEK adapted 
IBV-33 (Table 6). Tissue smears prepared after the second 
aerosol exposure were negative, including the smear from 
bird no. 5362. 
Serologic response 
Chickens exposed to CEK adapted IBV-33, generally de­
veloped significant PR-NI titers of 1.5 or greater within 
2 weeks following the initial aerosol exposure (Table 7). 
One bird (no. 5331) exposed to 33-89 and 3 birds (no. 5362, 
5329, 5232) exposed to 33-217 did not attain a PR-NI titer 
higher than 0.8 within the 2 weeks. At 4 weeks there were 
only 2 birds (no. 5362, 5262) that had PR-NI titers below 
1.5, while at 6 weeks all birds had titers in excess of 1.5. 
Only one bird (no. 5262) had a drop in its PR-NI titer to a 
negative level at 10 weeks. 
Response to challenge 
Respiratory signs were not observed after challenge in 
any birds from which tissue samples were obtained. Remain­
ing birds appeared to have normal respiration. 
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Table 7. Serologic response of chickens to 2 aerosol expo­
sures of CEK adapted IBV-33 and challenged 6 weeks 
later with the same strain. 
Passage Bird Weeks following initial exposure 
level no. 2 4^ 6 10^ 12 
5261 2.4C 2.7 3.3 3.5 4.5 
5059 2.1 2.8 3.4 3.5 
5246 3.0 3.4 3.7 3.7 4.8 
5064 2.6 2.9 3.5 3.5 5.6 
5090 2.6 3.3 K 
5495 3.6 3 . 3  3.5 3.6 K 
5466 2.2 2.7 3.4 2.7 K 
5028 2.5 D® 
5233 2.5 3.0 3.4 3.3 K 
5236 2.6 3 . 8  3.6 3.6 K 
5089 2.9 2.5 3.2 1.7 4.7 
5179 2.0 3.8 3.5 3 . 8  K 
5266 2.2 2.8 3.3 3.4 4.6 
5060 2.7 2.8 3 . 4  3.4 D 
5511 3.0 3 . 3  3.3 3.5 K 
^Time of second exposure. 
^Time of challenge. 
^Titers are expressed in PFU's. 
d 
Killed since last test. 
®Died since last test. 
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Tabic 7. (continued) 
Passage Bird Weeks following initial exposure 
level no. 2 4 6 10 12 
33-46-20 5192 2.2 3.3 K 
5268 2.5 3.3 K 
5265 3.3 3.3 3.5 3.4 5.6 
5096 2.6 3.8 3.6 3.7 K 
5249 2.7 2.9 K 
5238 2.5 3.8 3.6 3.6 D 
33-89-20 5062 2.1 2.7 3.4 3.6 K 
5475 2.3 2.2 3.7 3.5 K 
5056 1.9 3.1 3.5 3.5 4.7 
5104 2.3 2.7 3.3 3.6 K 
5448 2.2 2.6 K 
5179 2.0 1.8 3.3 3.6 5.3 
5053 2.4 2.3 3.8 3.6 5.3 
5068 2.4 2.9 3.3 3.3 4.3 
5252 2.2 2.6 K 
5407 1.9 2.9 K 
5400 2.3 2.9 3.4 3.3 K 
5237 2.1 2.2 3.5 2.9 K 
5488 3.6 4.8 D 
5229 2.1 2.7 3.2 3.3 4.7 
5069 2.5 3.0 K 
Table 7. (continued) 
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Passage 
level 
33-89-20 
33-147-20 
Bird Weeks following initial exposure 
no. 2 4 6 10 12 
5487 2.5 2.9 3.7 3.4 4.8 
5047 2.1 3.5 3.5 3.6 K 
5390 2.4 2.6 3.3 3.6 4.7 
5331 0.8 2.7 3.4 3.8 K 
5373 2.4 2 . 6  3.1 3.5 K 
5071 2.3 2.4 3.3 3.5 5.3 
5326 2.6 2 . 8  3.6 3.6 4.7 
5063 2.3 3.1 3.3 3.3 5.3 
5181 2.5 2.3 3 . 3  3.6 K 
5051 3.6 2.6 3.6 3.6 K 
5231 2 . 3  3.2 3.6 3.3 4.5 
5242 1.8 2 . 8  K 
5070 2.3 3.1 3.9 3.4 4.6 
5481 2.5 3.0 K 
5226 2.2 2.9 3.5 3.4 4.4 
5240 1.1 2.5 3.3 3.4 K 
5473 2.1 3 . 3  3.7 3.5 4.8 
5408 2.8 D 
5081 1.9 3.0 3.3 3.3 K 
5095 2.5 3.3 K 
5061 2 . 2  2.2 3.2 3.3 4.8 
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Table 7. (continued) 
Passage Bird Weeks following initial exposure 
level no. 1 Î o ID 17 
33-147-20 
33-217-20 
5032 3.0 3.6 3.9 4.0 K 
5258 1.9 3.3 3.5 3.5 K 
5348 2.6 3.6 K 
5381 2.5 3.3 3.3 3.5 5.0 
5031 2.7 2.6 3.5 3 . 3  K 
5347 3.0 2.6 2.9 1.8 K 
5362 0.5 1.0 K 
5091 2.4 3.0 3.5 3.5 K 
5026 2.6 2.1 3.0 3 . 2  K 
5456 2.0 1.9 3 . 6  1.7 K 
5264 N.D. f 2.5 3.5 3.4 K 
5092 2.0 2.6 3.7 3.6 K 
5470 2.3 3.0 K 
5248 2.2 2.7 3.4 3.2 4.2 
5520 2.1 2.9 3.5 3.3 5.3 
5262 2.0 1.1 2.2 0.7 4.1 
5364 1.2 1.7 3.7 3.2 K 
5329 0.7 D 
5359 1.7 2.7 3.4 3.3 5.3 
5334 2.0 D 
%ot done. 
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Table 7, (continued) 
Passage Bird Weeks following initial exposure 
level no. 2 4 6 10 12 
33-217-20 5232 0.7 
5467 2.3 
5357 2.1 
5243 2.1 
5263 1.8 
5074 2.0 
5188 1.6 
1.7 K 
3.0 K 
2.8 3.6 
3.2 3.4 
2.3 3.2 
1.6 3.3 
1.8 3.3 
3.5 5.0 
3.5 5.0 
1.9 5.0 
3.4 K 
3.3 K 
Isolation of virus from tracheal samples (Table 8) of 
birds previously exposed to 33-46-20 were successful except 
for the 24 hour sample of one bird (no. 5495). Five of 8 
lung samples were positive, while 3 of 8 kidney samples were 
positive. Virus was isolated from 5 of 8 tracheal samples 
from birds previously exposed to 33-89-20. Half of those 
samples taken at 48 hours or later (no. 5331, 5104, 5237) 
were negative for virus isolation. Virus was isolated from 
2 (no. 5047, 5475) lung and 2 (no. 5047, 5331) kidney sam­
ples. Virus was isolated from 5 of 8 tracheal, 3 (no. 5032, 
5051, 5031) lung and 1 (no. 5032) kidney samples from birds 
previously exposed to 33-147-20. Three (no. 5258, 5031, 
5240) of 4 tracheal samples obtained after 72 hours did not 
contain virus. Virus was isolated from 6 of 8 tracheal, 
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Table 8. Detection of virus in selected tissues of chickens 
immunized with CEK adapted IBV-33 and challenged 6 
weeks later with the same strain, using immuno­
fluorescence and chicken embryo inoculation. 
Passage Bird Hours Tissue 
level no. after Trachea Lung Kidney 
challenge klUgo FA EID50 FA EID50 FA 
33-56-20 5495 24 0
 
00
 
1 1.2 - 0.6 
5236 2.6 - 1.8 - 0.0 
5059 48 1.5 - 0.8 3.3 
5511 3.0 3.3 0.0 
5179 72 2.2 + 0.3 1 
0
 
0
 
5096 1.2 1.2 1.4 
5466 96 1.4 - 1.4 - 0.6 
5233 2.3 0.0 1.2 
33-89-20 5047 24 2.5 - 2.4 - 1.4 
5373 2.3 0.6 
0
0 0
 
5062 48 3.0 + 0.6 - 0.0 
5331 0.8 
0
 
0
 1.2 
5475 72 + 
00 
1.8 - 1 
0
 
0
 
5104 0.8 0.0 0.0 
5237 96 0.8 - 0.8 0.6 
5400 3.0 0.0 0.0 
33-147-20 5032 24 1.2 - 1.4 - 1.2 
5347 3.3 0.6 0.0 
•(-) Negative, (+) Positive. 
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Table 8. (continued) 
Passage Bird Hours Tissue 
level no. after Trachea Lung Kidney 
challenge tiUso HA tiiUso f A  hiUgQ FA 
33-147-20 5051 48 2.4 + 2.2 - 0.0 
5081 3.2 0.0 0.8 
5181 72 1.5 + 0.6 - 0.0 
5258 0.8 0.0 0.0 
5031 96 0.8 1.8 - 0.6 
5240 0.0 1.0 0.0 
33-217-20 5364 24 2.8 + 0.0 - 0.0 
5188 2.6 0.0 0.0 
5026 48 3.0 - 0.0 - 1.6 
5264 1.6 0.0 0.0 
5091 72 73.5 + 2.5 - 0.0 
5074 0.6 0.0 0.6 
5456 96 2.2 + 0.0 - 0.8 
5092 0.6 0.6 0.8 
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1 (no. 5091) lung and 1 (no. 5026) kidney sample from birds 
previously exposed to 33-217-20. 
Intracellular IBV antigens were not observed in every 
tissue smear that was positive for virus isolation following 
challenge (Table 8). Fig. 8 (p.73) illustrates the number 
of cells generally observed in tracheal smears that were 
determined to be positive for intracellular IBV antigens. 
Tracheal smears stained with conjugated antiserum to 
normal chicken globulins were considered to be negative for 
intracellular globulins. 
Electron Microscope Examination 
of Negatively Stained IBV 
Particles from cell culture fluid being few in number, 
were seen singly (Fig. 9A) or as doublets (Fig. 9B). Allan­
toic-amniotic fluid contained a moderate number of particles, 
which were observed singly (Fig. lOA) or in clumps (Fig. 
lOB). Particles from both culture methods closely resembled 
each other. 
A slight pleomorphism was observed, but the majority 
of particles were roughly circular. Club projections, so 
characteristic of IBV were observed covering approximately 
95 percent of the particles. The remaining particles were 
either partially covered or entirely void of projections. 
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Disrupted particles or internal structures were not 
observed. Measurement of particles or projections were 
not accomplished. 
Fig. 9. (Top) CEK propagated IBV-33-46-20. 
A. Two virus particles, one has consider­
ably more projections than the other. 
(X110,000) . 
B. Two slightly pleomorphic virus particles. 
CX240,Û00). 
Fig. 10, (Bottom) Chicken embryo propagated IBV-33-9. 
A. A single virus particle with well 
defined projections. (X260,000). 
B. Projections of massed virus particles 
appear to be clustered on the surface. 
(X150,000). 
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DISCUSSION 
Adaptation of IBV-33 to CEK cells appears to be accom­
plished without difficulty, if the inoculum has been suffi­
ciently adapted to chicken embryos. Cytopathic effect was 
observed during the first passage of all 4 egg passage lev­
els used as inoculum. Time required for cytopathic effect 
to appear is in accord with results reported by Chomiak e^ 
al. (32} and Churchill (38} using IBV-42. Virus titers ob­
tained in the first CEK passage of 33-46 and 33-217 varied 
by 1 logiQ, but the ELD50 the two inocula varied by 0.2. 
The exact reason for this difference of virus titers in CEK 
cells is not known. However, Hirst (102} states that studies 
on attachment of animal viruses are complicated by the fact 
that not all viral particles can express themselves as infec­
tive units. Other factors to consider are the effects of 
temperature and electrolytes on attachment. 
Delaplane and Stuart (9} established that successive 
passage of IBV in chicken embryos resulted in an increased 
lethality for the embryo, with an accompanying decrease in 
virulence for the chicken. Successive passage of IBV-33 in 
CEK cells did not appreciably alter the infectivity for 
chicken embryos. It was observed in several passages of 
33-147 and 33-217 that PFU titers were higher than ELD^g 
titers. The amount of change in virus titers does not appear 
to be significant up to the 20th passage in CEK cells. 
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Churchill (38) using IBV-42 in the 280th chicken embryo pas­
sage and 26 chicken kidney passages could not demonstrate any 
marked reduction in sensitivity between chicken embryos and 
chicken kidney cells for cell cultured IBV. Chomiak ejt al. 
(32) using IBV-42 after 242 chicken embryo passages and 10 
CEK passages, found that cell culture fluid virus, titered 
d 7 7 10 in cell cultures and 10 in chicken embryos. They con­
cluded that cell culture propagated virus remained as lethal 
for embryos as the embryo propagated virus. Results of this 
study were similiar to those reported by Churchill (38). 
All studies testing the efficacy of BPL inactivated IBV 
vaccines have used strains of the Massachusetts type. Chick­
ens of various ages and sex combinations have been vaccinated 
intramuscularly with 1, 2 or 3 doses of these vaccines. In­
tervals between doses have also varied greatly. The ability 
of BPL inactivated IBV to induce synthesis of a significant 
PR-NI titer in immunological competent chickens has been 
variable. It was therefore, encouraging to find that BPL in­
activated IBV-33 when given either simultaneously as an aero­
sol exposure and subcutaneous inoculation or alone by subcu­
taneous inoculation produced the following results: (1) in­
duced synthesis of significant PR-NI titers of 1.5 or greater 
and (2) a more persistent PR-NI titer was induced by a combi­
nation of aerosol exposure and subcutaneous inoculation than 
that induced by subcutaneous inoculation alone. An aerosol 
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exposure of BPL inactivated IBV-33 failed to produce a sig­
nificant PR-NI titer. Subcutaneous inoculation in the neck 
region was demonstrated to be a satisfactory method of immu­
nization. This is supported by the development of PR-NI 
titers of 1.5 or greater, in birds immunized using this 
method. 
In the present work, serum neutralizing antibodies pro­
duced by inactivated IBV-33 were readily detectable using 3 
Massachusetts type strains as antigen (IBV-33, IBV-41, 
IBV-42), in a PR-NI test in CEK cells. These results agree 
with those reported by Berry (61, 62), McDougall (67) and 
Box and Barnes (65) that inactivated IBV (Iblin) will pro­
duce detectable serum neutralizing antibodies using IBV-41 
and IBV-42 as antigen in virus neutralization tests in chick­
en embryos. However, Box and Barnes (65) reported that 
IBV-41 is a better antigen for this type of test than IBV-42. 
The present study found no difference in PR-NI titers using 
the two strains as antigen. Winterfield (63) using IBV-41 
and Brion e^ aJ. (69) using IBV-42 as antigen, could not de­
tect any serum neutralizing antibodies in chickens immunized 
with Iblin. Hromatka and Raggi (70) using Iblin reported 
negative results when the DA strain of IBV was used as anti­
gen. 
There appears to exist antigenic relationships between 
serotypes of IBV as evidenced by detection of PR-NI titers 
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of 1.5 or greater using IBV-97 and IBV-46 as antigens. How­
ever, this seems to be a temporary situation as significant 
PR-NI titers were not detectable at 4 weeks, were present at 
6 weeks and had declined to a negative status at 10 weeks 
(Table 4) . 
Criteria for evaluating immunity to IBV have been based 
on serum neutralizing antibodies and absence of respiratory 
signs after challenge. Chang e;t al. (83) studied other cri­
teria for evaluating immunity to IBV such as gross and histo-
pathological lesions in the trachea and isolation of virus 
from tracheal exudates and lungs following challenge. Their 
conclusions were that each test procedure was of limited 
value at any one time and none were effective during the 
entire sampling period. 
When respiratory signs were used as a single criterion, 
all three groups given BPL inactivated IBV-33 would be con­
sidered susceptible. Serologic results indicate that all 
birds, except those that were aerosol exposed would have 
some degree of immunity, due to the presence of PR-NI titers 
of 1.5 or greater. Isolation of virus from the tracheal 
samples show that 50 percent of the birds given the combi­
nation of aerosol exposure and subcutaneous inoculation were 
immune. However, lung tissue from bird no. 5050 yielded 
virus in low titer even though no virus was isolated from 
the trachea. The low titer obtained from the lung and the 
94 
and the negative isolation from the trachea indicated that 
this bird had some degree of immunity. 
Results obtained with BPL inactivated IBV-33 given in 2 
doses via aerosol exposure and subcutaneous inoculation are 
encouraging and warrant further investigation. In using 
this combination it is believed that the aerosol exposure is 
sufficient to sensitize and initiate an immune response in 
tracheal epithelium. This stimulation is probably of short 
duration, as it is believed that these antigens are rapidly 
assimilated by macrophages. Inoculation and the slow re­
lease of antigens from the IBV inactivated vaccine are suf­
ficient to enhance the immunological process initiated by 
the aerosoled antigens. 
Aerosol exposure of CEK adapted IBV-33 regardless of 
egg passage level was capable of inducing mild respiratory 
signs, such as wheezing. These respiratory signs were pre­
sent through 96 hours after exposure, but were not as se­
vere or as persistent as those described by Winterfield (91), 
using egg adapted IBV-41 (60th egg passage), IBV-46 (16th 
egg passage and Ri (60th egg passage) instilled into the 
trachea. Hofstad (90) using 3 aerosol exposures of egg 
adapted IBV-33 (86th, 45th, 4th egg passage) did not detect 
any respiratory signs. Raggi and Bankowski (103) using 7 
commercial vaccines found that respiratory signs persisted 
for 30 days or more, depending on the method of inoculation 
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vaccine strain, susceptibility and age of the bird. Respira­
tory signs as a symptom of IBV infection appears to be a 
combination of one or more of the following: (1) strain of 
IBV, (2) passage level, (3) method of inoculation, (4) depth 
of penetration of the inoculum and (5) age of the bird. 
Persistent neutralizing antibodies, induced by live CEK 
adapted IBV-33 were comparable to those obtained in birds 
exposed to egg adapted IBV (90, 91). A direct relationship 
between serum neutralizing antibodies and immunity was demon­
strated by giving a second exposure of the same virus 4 weeks 
later. Respiratory signs were not observed in any of these 
birds and only 1 of 8 tracheal samples was positive for 
virus. This bird did not respond immunologically, as no de­
tectable PR-NI titer was noted. Although the second exposure 
was not with a virulent virus, reinfection was prevented. 
Raggi and Lee (84) in a study of relationship of serum 
neutralizing antibodies and response to challenge of birds 
vaccinated with 3 strains of IBV, found a direct correlation 
with only 1 of the 3 vaccines tested. 
Challenge by instillation (73) and aerosol (80) of a 
predetermined EID50 or chicken infective doses (90) of egg 
propagated IBV gives satisfactory results in determining 
immunity of vaccinated chickens. Challenge by contact ex­
posure with infected birds gave satisfactory results in this 
study. It is believed that the latter method more closely 
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resembles a natural occurring spread of IBV, than do either 
aerosol or virus instillation via the nasal cavity or the 
trachea. The amount of virus each vaccinated or susceptible 
control receives cannot be quantitated, but neither can a 
natural spread of IBV through a flock of chickens. 
Challenged birds would be considered to have a high de­
gree of immunity if respiratory signs and PR-NX titers of 1.5 
or greater were the only criteria considered. However, virus 
was isolated from trachea, lung and kidney samples obtained 
from challenged birds. Virus titers obtained exceeded those 
reported by Hofstad (90) for the same time interval, using 
similiar methods of tissue processing. Winterfield (91) re­
covered virus from tracheas of birds vaccinated and chal­
lenged with IBV-41 and birds vaccinated and challenged with 
IBV-46, 96 hours after challenge. His method of virus iso­
lation was by swabbing the trachea. The length of time which 
elapses between challenge and attempted virus isolation seems 
to be an important factor. Hofstad (90) reported he was able 
to recover virus from the tracheas and lungs up to 3 days, 
but was absent at 96 hours. 
From results obtained a degree of immunity does exist 
in all chickens which were exposed to CEK adapted IBV-33. 
This immunity increases in each group which was exposed to 
CEK adapted virus obtained from inoculum in excess of 46 egg 
passages. Further experiments using CEK adapted IBV in high 
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egg passage, with exposure and challenge at shorter intervals. 
This is based on results reported here, that reinfection by a 
second exposure at 4 weeks after the initial exposure was in­
hibited . 
Intracellular IBV antigens were detected in tracheal 
and lung smears that had virus titers of 10®*^ PFU/ML or 
greater, following the first aerosol exposure to CEK adapted 
IBV-33. But, no correlation existed between virus isolation 
titers and fluorescent positive cells in challenged birds 
(Tables 5 and 8). IBV antigens are presumed to be present 
in these tissues, due to the isolation of virus. Reasons 
for the inability of specific conjugated antiserum to recog­
nize these antigens are not known. Similiar results have 
been reported by Lucio and Hitchner (49) using tracheal smears 
of chickens exposed to egg propagated IBV. 
Hofstad (86, 90) states that from studies conducted by 
him, it would appear that immunity against IBV depends more 
on previous exposure of the respiratory epithelium than to 
circulating antibodies. Johnson et (104) in titrating 
IBV in tracheal cultures of immune and susceptible chickens 
could not demonstrate local immunity to infection iji vitro. 
A more recent report by Heuschele and Easterday (105) using 
immunofluorescence demonstrated globulins and specific anti­
body to Newcastle disease in mononuclear cells, mucosa 
glands and mucus in tracheal mucosa of chickens exposed to 
9 8  
Newcastle disease virus aerosols. In results reported here 
tracheal smears of challenged birds were examined for intra­
cellular globulins without success. It is believed that if 
a purer preparation of chicken globulins were used to pre­
pare the antiserum, then the conjugated antiserum used in a 
sandwich technique, may reveal immune globulins in tracheal 
mucosa of chickens recovered from an infection with IBV. 
The evidence obtained in this study suggests that the 
particles of IBV cultivated in chicken embryos and CEK cells 
are morphologically similiar. Knob-like or bulbous distal 
ends of the projections could not be interpreted as being 
pear shaped as reported by Berry e^ al. (5). Lability and 
fragility in the concentration procedure and a tendency of 
the virus particles to accumulate in clumps were not pre­
valent in this study, as reported by Estola and Weckstrom 
(54) . 
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SUMMARY 
The immune response in susceptible White Leghorn Chickens 
was studied following immunization with either BPL-inactivated, 
egg propagated or live CEK adapted IBV, strain 33. 
Three groups of chickens were given 2 doses of BPL in­
activated IBV by one of the following methods: (1) aerosol 
exposure, (2) subcutaneous inoculation and (3) a combination 
of methods 1 and 2 given simultaneously. PR-NI titers of 
1.5 or greater to 3 strains of the Massachusetts type were 
obtained 2 weeks following the second dose. Respiratory 
signs were observed in all birds challenged by contact with 
infected birds. Isolation of virus from trachea, lung and 
kidney tissue of challenged birds, gave variable results. 
The best immunity was considered to be induced by the combi­
nation immunization method. 
Adaptation and propagation of 4 egg passage levels of 
IBV-33 in CEK cells did not affect infectivity for chicken 
embryos. One aerosol exposure with CEK adapted IBV was 
sufficient to prevent reinfection of trachea, lung and kidney 
tissue by a second aerosol exposure of the same preparation 
4 weeks later. All birds had developed PR-NI titers greater 
than 1.5 prior to challenge. Respiratory signs were not 
observed following challenge by contact exposure with infect­
ed birds. Isolation of virus from trachea, lung and kidney 
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tissues were similar to those observed in birds immunized 
with BPL-inactivated IBV, but of lower titer. Based on virus 
isolation results it appeared that a better immunity was 
induced by CEK adapted IBV, derived from 33-89, 33-147 and 
33-217, than with 33-46. 
Intracellular IBV antigens were observed in trachea and 
lung smears of chickens immunized with live virus and poss-
n Q 
essing virus titers of 10^* PFU/ML or greater using immuno­
fluorescence. No correlation could be detected between 
intracellular antigens and virus isolation titers from 
trachea, lung and kidney tissues from challenged birds that 
were immunized with either inactivated or live virus. 
IBV-33 cultivated in chicken embryos and CEK cells, 
when negatively stained and examined in the electron micro­
scope, appeared to have similar morphologies. 
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